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Age-related macular degeneration (AMD) is a major cause of irreversible central sight 
loss in the elderly. Many factors affect disease onset and progression, and these include 
age, environmental stressors such as smoking, diet, inflammation and genetic 
polymorphisms, all of which are likely to influence metabolism. In some complex 
diseases, metabolomics, which involves the identification of a metabolic fingerprint in a 
biofluid or tissue, has been shown to discriminate metabolic changes associated with 
different disease processes and to identify specific phenotypes. We have applied 
metabolomics, in the first study of its kind, to analyse, using NMR spectroscopy, both 
serum and urine metabolic characteristics in patients with dry and wet AMD (n=104). 
NMR spectral analysis showed good clustering as well as separation among the serum 
and urine from dry and wet AMD patients. The results show that metabolite profiles can 
distinguish dry and wet AMD, but that the pathways involved, glycolysis, urea cycle and 
Kreb’s cycle, are involved in both forms of the disease. It is likely that the pathogenesis 
of dry and wet AMD is similar and that the severity of ocular damage and systemic 
inflammation would account for the distinguishing profiles. These data support the use of 
metabolomics in identifying biological pathways involved in pathogenesis of AMD, but 
not in the diagnosis or prognosis of disease. 
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A. MACULAR DEGENERATION: AN OVERVIEW 
Age-related macular degeneration (AMD) is a major cause of ocular morbidity in the 
elderly in developed countries, causing irreversible central sight loss. It is thought to 
affect more than 3 million people in the United States by 2020 (Eye Diseases 
Prevalence Research Group, 2004).  The prevalence study of late AMD in the United 
Kingdom by Owen et al showed overall prevalence of late AMD to be 2.4%, equivalent 
to 513 000 cases, estimated to increase to 679 000 cases by 2020 (Owen CG et al., 
2012).  
In this chapter, I have briefly outlined the following: 
1. Anatomy of macula and choroid 
2. Macular degeneration: types and new classification 
3. Pathophysiology of AMD 
4. Role of risk factors in the pathogenesis of AMD 
5. Diagnosis of AMD 
6. Treatment of AMD 
 
1. Anatomy of macula and choroid 
The eye consists of three layers: an outer layer of sclera and cornea; a middle layer 
consisting of iris, ciliary body and choroid (uvea); and an inner layer, the retina, the 
light sensitive layer of the eye. Near the centre of the retina is the macula, a 5-6 mm 
wide area, rich in xanthophyll pigments, lutein and zeaxanthin (Provis J et al., 2005). 
The macula is responsible for photopic and colour vision and provides the greatest 
 
3 | P a g e  
 
resolving power of the eye. The macula is located inside the temporal vascular arcades, 
2 disc-diameters temporal to the optic disc; the centre of macula is called fovea (Figure 
1.1). 
 
Figure 1.1: Anatomy of retina 
The retina consists of an outer retinal pigment epithelial layer (RPE) and an inner neuro 
sensory layer. The primary layers of the retina, from outermost surface to innermost 
surface, are as follows (Figure 1.2): 
• Retinal pigment epithelium (RPE): these are the supporting cells for the neural 
portion of the retina 
• Rod and cone layer or Layer of photoreceptor cells: this contains the outer 
segments and inner segments of the rod and cone photoreceptors 
• Outer limiting membrane  
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• Outer nuclear layer (ONL): contains cell bodies of rods and cones 
• Outer plexiform layer (OPL): contains rod and cone axons, horizontal cell 
dendrites and bipolar dendrites 
• Inner nuclear layer (INL): Nuclei of horizontal, bipolar and amacrine cells 
• Inner plexiform layer (IPL): axons of bipolar (and amacrines), dendrites of 
ganglion cells 
• Layer of ganglion cells (GCL): Nuclei of the ganglion cells and 
displaced amacrine cells 
• Layer of optic nerve fibres: contains fibres from ganglion cells traversing the 
retina to leave the eyeball at the optic disc 
 
Figure 1.2: Layers of retina as seen in optical coherence tomography (OCT) 
(Image courtesy of Jessica G. Lee, MD and the Photography Department at 
New York Eye and Ear Infirmary of Mount Sinai, July 2015) 
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Photoreceptor cells, RPE cells, Bruch’s membrane (BrM), and choriocapillaris are 
interdependent layers of the outer retina, which contribute to normal vision, and are 
affected in ageing process and macular degeneration (Chirco KR et al., 2017).  
Photoreceptor cells are highly metabolically active cells converting photons to electrical 
impulses, which requires constant regeneration of their outer segments. Photoreceptor 
cells are normally lost with ageing in healthy retina, however this happens at an 
accelerated rate in the central 1mm of macula in macular degeneration (Chirco KR et 
al., 2017; Curcio C, 2001). 
The retinal pigment epithelium (RPE) is a single layer of hexagonal epithelial cells with 
densely packed pigment granules. They are tall and narrow columnar epithelial cells in 
the macula, becoming more cuboidal outside the macula. The microvilli on the apical 
surface of the RPE cover the photoreceptor outer segment and support in their turnover. 
The hemidesmosomes in the basal aspect of the RPE anchor them to the basal laminae; 
this forms the innermost layer of the Bruch’s membrane (Chirco KR et al., 2017). 
RPE cells phagocytose and recycle the shed photoreceptor outer segments. The RPE 
absorbs excess light, converting all-trans retinol to 11-cis retinal as part of the visual 
cycle, and secretes growth factors to maintain photoreceptor cells and the choroidal 
vasculature. Further, RPE cells transport nutrients and waste material between 
photoreceptor cells and choriocapillaris and form the outer blood–retinal barrier (Bok, 
1993).  
With ageing, pigmentation in the RPE cells is altered through loss of melanosomes, 
increase in lipofuscin granules and increase in toxic by-products of the visual cycle. 
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Bruch’s membrane 
Bruch’s membrane (BrM) is a 2-4 μm-thick extracellular matrix complex that separates 
the RPE and choroid. It is composed primarily of elastin and collagen. BrM consists of 
the following five distinct layers: (1) the RPE basement membrane (innermost layer), 
(2) the inner collagenous layer, (3) the elastic layer, (4) the outer collagenous layer, and 
(5) the choriocapillary endothelial cell basement membrane (outermost layer) 
(Nakaizumi Y,1964).  
The BrM contains a reservoir of anti-angiogenic molecules such as thrombospondin-1 
(TSP-1), angiostatin, endostatin, and pigment epithelium-derived factor (PEDF); this 
reservoir acts both as a barrier that prevents cell migration from retina or choroid, and 
as a filter that controls passage of various molecules between RPE and choroid. BrM 
also provides a surface for RPE cell adhesion, growth, and physical support (Prea S et 
al., 2015). 
Choroid 
The choroid is the vascular bed that lies just beneath the RPE, between BrM and the 
sclera. It is composed of blood vessels, melanocytes, fibroblasts, immunocompetent 
cells and supporting collagenous and elastic connective tissue. The vascular region of 
the choroid consists of the outer Haller's layer of large blood vessels and the inner 
Sattler's layer of medium and small arteries and arterioles that feed the capillary 
network and veins. The stroma (extravascular tissue) contains collagen and elastic 
fibres, fibroblasts, non-vascular smooth muscle cells and melanocytes. The capillary 
bed (the choriocapillaris) which makes up the innermost layer of the choroid provides 
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the principal blood supply, thus delivering oxygen to the outer retina (RPE and 
photoreceptor cells). Other functions of the choroid include light absorption, 
thermoregulation via heat dissipation, and modulation of intraocular pressure (IOP) via 
vasomotor control of blood flow. The choroid also plays an important role in the 
drainage of the aqueous humour from the anterior chamber, via the uveoscleral 
pathway. The loss of choriocapillary endothelial cells is a key contributor to the 
development of AMD. 
 
2. Macular degeneration  
Age-related macular degeneration (AMD) is a painless, irreversible, degenerative 
disease of the macula, resulting in loss of central vision, which is essential for our daily 
activities including reading and driving. Early AMD often is asymptomatic, however 
most eyes with choroidal neovascularisation (CNV) due to AMD under the fovea 
become legally blind within two years of diagnosis, many within months. 
Socioeconomic impact of sight impairment 
In 2013, there were an estimated 1.93 (1.58 to 2.31) million people with sight loss and 
blindness in the UK (2.5% to 3.6% of the population) (Pezzullo L, 2018), AMD being 
the leading cause of blindness (Owen C, 2003). From 2013 to 2050, the share of sight 
loss and blindness from AMD is projected to change from 23.1% to 29.7%, more than 
doubling from 445,809 (363,900 to 532,800) people to 1.23 (1.01 to 1.47) million 
people (Pezzullo L, 2018). The cost of detection, treatment and provision of state and 
family social care for everyone with AMD was more than £1.6bn in 2010. The 
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estimated cumulative cost over the decade from 2010 to 2020, is expected to rise to 
£16.5bn due to demographic change: while the healthcare treatment component 
amounts to 18% of the total (more than £2.9bn), the personal and social costs make up 
76% (more than £12.5bn) (Minassian D, 2009). 
Types of AMD 
Previously, AMD was described to be either ‘dry’ with no neovascularisation, or ‘wet’ 
in which new vessels from the choroid disrupt retinal tissue. Dry AMD is associated 
with gradual visual loss, while wet AMD is associated with sudden and severe visual 
loss.  
New classification of AMD 
In 2013, the Macular Research Classification Committee proposed a new clinical 
classification for macular degeneration, based on fundus lesions assessed within 2 disc-
diameters of fovea in patients over 55 years of age. The committee agreed that a single 
term, age-related macular degeneration, should be used for the disease. Using a 
modified Delphi technique, the committee developed a 5-stage AMD classification 
scale: no apparent ageing changes, normal ageing changes, early AMD, intermediate 
AMD or late AMD (Table 1.1) (Ferris FL et al., 2013).  
Persons with no visible drusen or pigmentary abnormalities should be considered to 
have no signs of AMD. Persons with small drusen (<63 μm), also termed drupelets, 
should be considered to have normal ageing changes with no clinically relevant 
increased risk of developing late AMD. Persons with medium drusen (≥ 63 - <125 μm), 
but without pigmentary abnormalities thought to be related to AMD, should be 
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considered to have early AMD. Persons with large drusen or with pigmentary 
abnormalities associated with at least medium drusen should be considered to have 
intermediate AMD. Persons with lesions associated with neovascular AMD (choroidal 
neovascularisation (CNV)) or geographic atrophy (GA) should be considered to have 
late AMD (Ferris FL et al., 2013). 
Table 1.1: Proposed new classification of age related macular degeneration. 
(Classification published by Ferris FL et al., 2013)  
 
Depending on the location of the CNV, it can be of 3 types. Type 1 or occult CNV is 
where CNV remains beneath the RPE monolayer but does not invade the photoreceptors 
and neural retina, whereas CNV that proliferates within the sensory retina is termed 
classic or type 2 CNV (Wang H, 2016; Grossniklaus HE, 2004). Vascular lesions 
Classification of AMD Definition  
(lesions assessed within 2 disc-diameters of fovea in 
either eye) 
No apparent ageing 
changes 
No drusen; and 
No AMD pigmentary abnormalities 
Normal ageing changes 
Only drupelets (small drusen ≤63 μm); and 
No AMD pigmentary abnormalities 
Early AMD 
Medium drusen>63 μm and ≤125 μm; and 
No AMD pigmentary abnormalities 
Intermediate AMD 
Large drusen> 125 μm; and/or 
Any AMD pigmentary abnormalities 
Late AMD 
Neovascular AMD; and/or 
Any geographic atrophy 
 
10 | P a g e  
 
arising from the retinal vasculature in the deep retina is known as retinal angiomatous 
proliferation (RAP), or type 3 neovascularization (Wang H and Hartnett ME, 2016; 
Yannuzzi L, 2001). 
Drusen  
A characteristic feature of AMD is the presence in the retina of drusen, yellow deposits 
of lipids and proteins that accumulate with age. Increased size and number of drusen are 
associated with increased severity of disease (Oishi et al., 2017; Mullins et al., 2000).  
Drusen is composed of degradation products for photoreceptor cells, and RPE cells and 
immune processes, including serum amyloid P, immunoglobulin light chains and 
complement proteins (Anderson D et al., 2002). Drusen has been identified as 
inflammatory in the retina via infiltration and activation of macrophages a significant 
feature (Cruz-Guilloty F et al., 2013).   
Geographic atrophy  
Geographic atrophy (GA) is a manifestation of late-stage AMD, characterized by 
localized atrophy of retinal pigment epithelium, the overlying photoreceptors and the 
choriocapillaris, leading to central scotomas and permanent loss of visual acuity. In the 
early stages, when distance visual acuity (VA) is marginally reduced or indeed 
unaffected, patients with GA have trouble with reading and seeing in low-light 
conditions, problems that may not be reflected in VA measurements. Currently, there 
are no approved treatments to prevent GA or limit its progression when already present, 
nor are there any treatments that can reverse the pathology. Geographic atrophy is 
usually bilateral, with major impact on vision-related quality of life. 
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In our research we have categorised patients into two groups: those with choroidal 
neovasclarisation as wet AMD group and all the others (early and  intermediate AMD 
as well as late AMD without neovasclarisation (GA)) as the dry AMD group. 
 
3. Pathophysiology of AMD 
One of the changes seen in the macula of patients with early AMD is development of 
drusen. During ageing process, there is alteration of metabolism in RPE cells causing 
destruction of BrM and accumulation of extra cellular material between RPE and 
Bruch’s membrane, leading to the development of drusen.  
Histopathologic and proteomic analyses have shown increased deposition of  
compounds such as TIMP3 and SerpinA3, vitronectin, bisretinoid fluorophores, 
complement, oxidized proteins, lipoprotein derived debris, cholesterol esters and 7-
ketocholesterol, beneath the RPE cells and within Bruch’s membrane (Nita M et al., 
2014; Hageman GS and Mullins RF, 1999). 
Drusen can be nodular or diffuse. Nodular drusen consists of a focal thickening of the 
RPE basement membrane. In fluorescein angiography (FA), they cause early 
hyperfluorescence and late staining. Histologically, nodular drusen have an 
eosinophilic, PAS-positive appearance and are located externally or replace the thin 
basement membrane of the RPE (Guymer R et al., 1999).  
In diffuse drusen, materials get deposited between the basement membrane of the RPE 
and the inner collagen layer of the Bruch’s membrane. In FA, they are hypofluorescent 
due to lipid accumulation and later show staining (Guymer R et al., 1999). 
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Drusen and other extracellular deposits accumulate toxic substances which obstruct the 
passage of nutrients and oxygen from the choriocapillaris to the overlying RPE and 
retina, putting the RPE cells under stress (Guymer R et al., 1999). 
In the natural history of disease progression, the drusen accumulation is followed by 
hyperpigmentation and drusen regression, resulting in atrophy of RPE and 
choriocapillaris. This leads to photoreceptor cell loss and development of geographic 
atrophy (GA) (Klein ML et al, 2008).GA can remain stable over time, or progress 
quicker in volume and area before CNV develops.  
Some deposits located above the RPE, called reticular pseudodrusen or drusenoid 
subretinal deposits (Zweifel et al., 2010), do not fluoresce with fluorescein or 
indocyanine green in angiography. These can also precede GA due to  the damage to the 
RPE caused by the underlying atrophy and fibrosis of the choroid (Klein ML et al, 
2010). 
In neovascular AMD, hypoxia of the overlying RPE cells contributed by the loss of 
choriocapillaris, results in the release of angiogenic factors leading to the development 
of CNV (Bhutto I and Lutty G, 2012). The choroidal endothelial cells (CECs) migrate to 
and across the RPE monolayer and into the sensory retina where they proliferate and 
develop into CNV, anywhere between the choriocapillaris and neural retina. These new 
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4. Role of risk factors in the pathogenesis of AMD 
AMD is a multifactorial disease, with several factors attributed to the development and 
progression of AMD. Non-modifiable risk factors include age, family history and 
genetic factors including complement pathway and immunological factors. The 
modifiable risk factors are smoking, dietary factors, obesity, and underlying vascular 
risk factors such as high blood pressure and cholesterol. Recently, inflammation has 
also been suggested to play a role in the pathogenesis of AMD. 
Age 
AMD is a disease of the elderly, a cumulative outcome of several metabolic and cellular 
changes, likely to occur in individuals over the age of 60 years. The risk of developing 
AMD increases dramatically with age, the prevalence increasing to almost three-fold in 
those over 80 years of age (Owen CG et al, 2012). With ageing, gradual loss of retinal 
neuron cells, photoreceptors and RPE cells occur (Gao H and Hollyfield JG, 1992). In 
addition to cell loss, an increase in intra and extra cellular deposition of material has 
also been seen with advancing age. Lipofuscin, intracellular deposit in RPE, when 
exposed to oxygen and light, generate reactive oxygen species (ROS) (Boulton et al, 
1993), which is implicated in the pathogenesis of AMD. Lipofuscin has also been 
implicated in immune dysregulation via monocyte and microglial activation (Ma et al, 
2013). Another change noted with ageing is the transformation of classically activated 
M1 macrophages (anti-angiogenic) to M2 macrophages which contributes to aberrant 
inflammation, losing its ability to prevent angiogenesis (Kelly et al, 2007). Cholesterol 
intermediates activate alternative complement pathway, inciting inflammation and 
contributing to the pathogenesis of atherosclerosis, AMD and Alzheimer’s disease 
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(Sene A et al, 2013; Sharma et al 2014). These changes are not seen in the younger age 
group, further strengthening the theory that AMD is an ageing disease and not a 
developmental disease. 
Ethnicity 
Ethnicity is associated with disease risk, with Caucasians at a significantly higher risk 
of AMD than African-Americans in the United States, especially with regard to wet 
AMD. Global AMD prevalence by ethnic group is estimated as 12.3% for European 
ancestry, 10.4% for Hispanics, 7.5% for African ancestry, and 7.4% for Asians (Eye 
Diseases Prevalence Research Group, 2004; Owen CG et al, 2012). 
Smoking  
The risk of developing AMD in current smokers is two- or three-times the risk for 
never-smokers. There is a greater than four-fold increased risk for neovascular AMD in 
smokers (Velilla et al., 2013). Choroidal blood flow is reduced in AMD (Friedman E et 
al., 1995; Ciulla et al., 2002). Grunwald et al (2003) discovered an association between 
decreased circulation within the choroid and increased risk for wet AMD implicating 
ischemia in CNV formation. Smoking may also reduce choroidal blood flow in the eye, 
and promote ischaemia and hypoxia, further increasing the susceptibility of the macula 
to degenerative changes (Steigerwalt RD Jr et al., 2000).  Nicotine administration 
appeared to increase severity of experimental choroidal neovascularization in a mouse 
model (Suñer IJ et al., 2004). Smoking has also been shown to reduce macular pigment 
optical density, which reflects levels of the protective carotenoids, lutein, and 
zeaxanthin in the macular retina (Kirby ML et al, 2010).  
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Cigarette smoke contains high quantities of pro-oxidant benzene derivative 
hydroquinone. Incubation of RPE cells with hydroquinone induced an injury response 
similar to sub-RPE deposit formation. Exposure to hydroquinone also resulted in 
decreased levels of matrix metalloproteinase-2 and increased levels of collagen IV 
resulting in a net decrease in extracellular matrix turnover, causing thickening of 
Bruch's membrane or formation of sub-RPE deposits (Kirby ML et al., 2010). 
In an experimental mice model with laser induced CNV, there was a statistically 
significant increase in the size of CNV in those exposed to cigarette smoke compared to 
control models (Suñer IJ et al, 2004). 
Cigarette smoking may increase the risk of AMD through enhancement of the immune 
cascade. Smoking leads to low levels of carotenoids in both blood and the retina, 
probably through a free radical dependent mechanism. The exposure to constituents of 
cigarette smoke increases the presence of proinflammatory cytokines like C- reactive 
protein (CRP), interleukin-6, soluble tumour necrosis factor alpha receptor 2, soluble 
intercellular adhesion molecule-1 (ICAM-1), and apolipoprotein B (ApoB) (Nita M and 
Grzybowski, 2016). Cigarette smoking has been shown to trigger the alternative 
pathway of complement activation and increase leukocyte recruitment in both 
endothelial and epithelial tissues (Kew RR et al., 1985). 
Role of inflammation 
Recent studies have shown a strong link between inflammation and diseases of ageing. 
The presence of activated microglia around the lesions in the chronic neurodegenerative 
disorders like Alzheimer’s and Parkinson’s diseases supported the role of inflammation 
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in these diseases. It was suggested that long-term use of non-steroidal anti-inflammatory 
drugs may be protective or may slow the onset of conditions such as Alzheimer’s 
disease and AMD (Wang J et al., 2015). 
Histopathological evaluation of AMD lesions has illustrated the presence of 
inflammatory cells including macrophages, mast cells, and lymphocytes. Anderson et al 
(2002) proposed that immune factors, with activation of the complement cascade and 
release of inflammatory mediators, contribute to the development of changes in the RPE 
and Bruch’s membrane, which in turn predispose to the development of AMD. They 
noticed an accumulation of C- reactive protein (CRP) and complement (C5) in the 
cytoplasm in a group of dying RPE cells. Their study also showed drusen containing 
both C3 and C3 activation fragments and complement reactivity in sub-RPE deposits 
associated with the collagen layers of the Bruch membrane (Anderson DH et al., 2002). 
Pentameric CRP (pCRP) is an acute-phase protein, whose level increases from <1 up to 
>500 μg/ml, with onset of inflammation. As a result, the serum-associated pCRP is 
commonly used as a biomarker for infection or inflammation, regardless of the cause. 
pCRP, when bound to activated platelets or apoptotic cells, dissociate into monomers 
(mCRP), loses its anti-inflammatory activity and adopt potent pro-inflammatory 
properties (Mitta VP et al., 2013). 
Macrophages are thought to play an important role in controlling the events in AMD. 
Macrophages are recruited to remove debris, thus preventing inhibition of RPE cell 
function and oxidative stress and to restore homeostasis in people with normal 
functioning immune system (Skeie JM and Mullins RF, 2009). However, in 
immunosenescence, when the normal regulatory control breaks down, parainflammation 
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ensues, resulting in suboptimal or altered function of the macrophages. It can result in 
either progressive RPE cell death with minimal inflammation (dry AMD) or enhanced 
inflammation by recruiting proinflammatory macrophages resulting in angiogenesis 
(wet AMD). The type of macrophages recruited depends on the cytokines released in 
response to the tissue injury: interleukins (IL) 1 and 18 are proinflammatory, while IL 
10 is anti-inflammatory.   
Elevated oxidative stress has been linked to several aging-related illnesses, including 
macular degeneration. The ability of a cell to resist oxidative damage is determined by 
the balance between the generation of reactive oxygen species and the defensive 
capacity to produce antioxidants. Glutathione is the most abundant endogenous 
antioxidant found within cells, playing a central defensive role against oxidative stress. 
When cells are unable to maintain intracellular glutathione concentrations, irreversible 
cell damage occurs. It has been noted that blood levels of glutathione are greatly 
diminished in ageing blood, indicating altered metabolic activity (Forrester JV, 2013; 
Skeie JM and Mullins RF, 2009).  Glutathione deficiency in aging results in an 
increased pro-oxidizing shift and elevated oxidative stress, but underlying mechanisms 
are not well understood. 
It is believed that lutein, zeaxanthin and meso-zeaxanthin in the macula block blue light 
from reaching the underlying structures in the retina, thereby reducing the risk of light-
induced oxidative damage that could lead to AMD. A nutritional supplement containing 
lutein, zeaxanthin and meso-zeaxanthin effectively increased the optical density of the 
macular pigment in eyes of most human subjects (Ma L et al., 2016). Another study 
concluded that lutein, zeaxanthin and meso-zeaxanthin filter short-wavelength light and 
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prevent or reduce the generation of free radicals in the retinal pigment epithelium and 
choroid. The study also suggested that a mixture of these carotenoids is more effective 
than any individual one at the same total concentration (Li B et al., 2010). 
Gene expression profiling of dermal fibroblasts from AMD patients showed no 
difference from controls until an oxidative or inflammatory insult was given 
(Strunnikova N et al., 2005). This gives an important insight into the possible 
interaction between environment and disease. This decline in biochemical protective 
mechanisms may relate to the low-grade inflammation, resulting in raised CRP, and 
such a decline is more profound in the apparently healthy elderly. This could result from 
metabolic changes in the liver, the major source of glutathione and CRP, or in the 
immune cell activity driving this process (Mitta V et al., 2013). Oxidative damage to 
docosahexanoic acid (DHA), which is found in abundance in the retina, leads to the 
production of carboxyethylpyrrole (CEP), which can bind to other self-proteins and act 
as a hapten. CEP modified proteins were shown to be more prevalent in eyes from 
donor with AMD compared to age-matched controls. Moreover, CEP altered proteins 
and anti-CEP antibodies are more abundant in patients with AMD. (Hollyfield JK et al., 
2008).  
Case control studies have shown 50% increase in AMD in age matched groups adjusted 
for cigarette smoking, when the measured high-sensitivity CRP (hsCRP) level was > 3 
mg/L. The study also showed a nearly 2-fold increased risk of neovascular AMD. This 
finding further supports the theory that low-grade systemic inflammation contributes to 
AMD development in the general population (Forrester JV, 2013; Hollyfield JG, 2008).  
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Advanced glycation end products (AGEs) are proteins or lipids that are covalently 
bound with sugar molecules. The AGEs are formed extracellularly via a non-enzymatic 
process. They accumulate in extracellular matrices, such as BrM, and disrupt normal 
protein function. Once AGE accumulation reaches a certain level, the AGE receptor 
(RAGE) can be engaged and activated. RAGE is present on many cell types, including 
endothelial cells and leucocytes, and its activation induces an inflammatory response 
that could help trigger the conversion from acute inflammation to chronic inflammation 
and tissue damage, and may have a role in angiogenesis (Howes KA et al., 2004). 
RAGE may also contribute to the activation of immune cells in laser-induced CNV 
lesion in a mouse model of AMD (Chen M et al., 2014). 
Intracellular adhesion molecule 1 (ICAM-1) is a glycoprotein expressed on the 
endothelial cells of the healthy choriocapillaris, especially within the macula. This is in 
contrast to other vascular beds where ICAM-1 is only expressed during an immune 
response. Elevated ICAM-1 in AMD could promote the recruitment of leukocytes into 
the choroid to evoke or propagate an immune response (Skeie JM et al., 2010). 
Complement system 
The complement system is a proteolytic cascade comprising approximately 40 plasma 
and cell surface-associated proteins involved in the elimination of pathogenic cells, 
dead cells, and other dangerous cellular debris from the body. 
The complement pathway can be activated by three routes: antigen-antibody complexes 
activate the classical pathway, lectins activate the lectin pathway, and foreign organisms 
activate the alternate pathway. These three pathways have distinct mechanisms of 
initiation, but they all utilize the same terminal pathway involving C5 cleavage. Once 
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C3 is cleaved and the levels of C3b begin to increase, C5 convertases are formed 
(C4b2a3b and C3bBb3b). These enzymes cleave C5 to generate C5a and C5b, C5b then 
interacts with C6, C7, C8, and many copies of C9 to form the membrane attack complex 
(MAC). MAC formation is the final step in complement activation and it results in 
target cell lysis. The complement cascade also produces potent anaphylatoxins (C3a and 
C5a), resulting in phagocyte recruitment and leukocyte and endothelial cell activation 
causing efficient clearance of lysed cells (Figure 1.3) (Chirco KR et al., 2017). Bora and 
associates (2006) reported the activation of alternate pathway in the development of 
CNV secondary to laser burn in a murine model (Bora NS et al., 2006).   
In proteomic studies of donor macula, TIMP3, the complement proteins C7, C5, and C9 
were found to be more abundant in BrM/ choroid tissue from early- or mid-stage AMD 
eyes compared with controls. In advanced wet AMD, however, complement C3 protein 
levels were elevated compared with controls. These suggests inflammatory processes, 
including complement activation, as early factors in disease progression with the 
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Figure 1.3: Overview of complement system. (Figure adapted from Chirco 
KR et al., 2017) 
 
Genetic factors controlling immune response in AMD 
Complement factor H (CFH) recognizes polyanionic structures such as sulfated 
glycosaminoglycans (GAG) found on host tissues, and thereby inactivates any C3b that 
becomes deposited. A single nucleotide polymorphism (SNP) in CFH (Y402H) has 
been strongly associated with an increased risk of AMD (Hageman GS et al., 2005). 
This polymorphism, involving a tyrosine-to-histidine coding change, alters the binding 
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of CFH to sulfated GAGs, as well as to other ligands including C-reactive protein, 
necrotic cells and bacterial coat proteins. Compared with 402Y allotype, the 402H 
allotype interacts less well with binding sites within the macula (e.g. Bruch's 
membrane). Reduced binding of the 402H allotype results in impaired regulation of 
complement leading to chronic local inflammation, accumulation of drusen and 
development of AMD. A single copy of the risk-associated haplotype increases the risk 
of AMD by two- to four-fold, whereas those with a dual copy may increase their 
lifetime risk by five- to seven-fold (Klein RJ et al., 2005). 
Donors homozygous for the high-risk CFHY402H polymorphism were found to have 
choroidal MAC levels 69% higher than that of the low-risk donors. The choroids of 
eyes homozygous for the high-risk CFHY402H allele have elevated MAC deposition in 
the choriocapillaris and are almost 24% thinner compared with low-risk eyes. This 
pointed to an association between the high-risk CFH genotype and increased choroidal 
atrophy, due to increase in MAC accumulation around the vessels in high-risk donor 
eyes (Mullins RF et al., 2011). 
The binding affinity between mCRP and mutant CFH (402H) is as much as 45% lower 
than that of mCRP and wild-type CFH (402Y) as the Y402H variation occurs in the 
CCP7 domain, which is one of the two CCP regions that interact with mCRP (Lauer N 
et al., 2011). 
Transforming growth factor-β (TGF-β) is a product of both immune cells and RPE cells. 
TGF-β plays a central role in the normal immunosuppressive intraocular 
microenvironment mediating the immune response and inhibiting proinflammatory 
responses in the eye (Stein-Streilein J, (2008).  The HTRA1 gene, a member of the high 
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temperature requirement A serine protease family, has been shown to play an important 
role as an antagonist of the TGF-β family proteins. DeWan and associates reported that 
a SNP in the promoter region of HTRA1 predisposes patients of Asian descent to AMD, 
with a 10-times greater risk compared to individuals with wild genotype (Dewan A et 
al., 2006). Of interest is the fact that the wet type of AMD, albeit more frequently seen 
without drusen or as a polypoidal variant, is more prevalent in the Asian than in the 
White population, and the complement factor H Y402H variant is seen less frequently 
in people with Japanese and Chinese ancestry (less than 5% compared with 
approximately 35% in White population) (Nussenblatt R and Ferris F, 2007; Ng TK et 
al., 2008). 
Age-related maculopathy susceptibility protein 2 (ARMS2) is a mitochondrial protein, 
the SNP of which is associated with wet AMD and the frequency of progression from 
dry to wet forms of the disease but are less associated with dry AMD. In a Spanish 
population, ARMS2 has been reported to be one of the principal risk factors for AMD 
(Fuse N et al., 2011). 
Weeks et al hypothesised that the effect of smoking on the risk of developing AMD is 
accentuated by a gene in the 10q26 region of the genome (Weeks DE et al., 2004). 
 
5. Diagnosis of AMD 
 
Clinical evaluation with slit lamp biomicroscopy with 90D or 78D lens, Optical 
Coherence Tomography (OCT), Fundus Fluorescein Angiography (FFA) and 
Indocyanine green angiography (ICG) are the main tools in the diagnosis of AMD. 
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Fluorescein Angiography 
H.R. Novotny and D.L. Alvis, two medical students, described the technique of retinal 
fluorescein angiography (FA) in 1961. Fluorescein dye is injected intravenously, 
usually through an antecubital vein. White light from a flash is passed through a blue 
excitation filter. Blue light (wavelength 465-490nm) is then absorbed by unbound 
fluorescein molecules, and the molecules fluoresce, emitting light with a longer 
wavelength in the yellow-green spectrum (520-530nm). A barrier filter blocks any 
reflected light so that the images capture only light emitted from the fluorescein. Images 
are acquired immediately after injection and continued for ten minutes depending on the 
pathology being imaged (Singerman L,1986). 
Based on the pattern of leakage seen in FA images, CNV can be classified as Classic 
showing intensely bright fluorescence in early phases of the angiogram and leaks in late 
phases and occult, in which leakage is less intense and appears in the late phases of 
disease (Macular Photocoagulation Study Group, 1991). 
Indocyanine green angiography 
Indocyanine green (ICG), a water-soluble, protein-bound dye, is retained in the 
choroidal circulation due to its low permeability. This makes ICG angiography ideal for 
imaging choroidal circulation. One advantage of ICG is its ability to fluoresce better 
through pigment, fluid, lipid, and haemorrhage than fluorescein dye. This increases the 
possibility of detecting abnormalities such as CNV that may be blocked by an overlying 
thin, sub-retinal haemorrhage or hyperplastic RPE on a fluorescein angiogram. This 
allows enhanced imaging in occult CNV and pigment epithelial detachments (Yannuzzi 
L et al., 1993). 
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Optical Coherence Tomography 
Developed in 1991, Optical Coherence Tomography (OCT) is the most valuable 
advance in retinal diagnostic imaging. It is a non-invasive imaging technique relying on 
low coherence interferometry to generate in vivo, cross-sectional imagery of ocular 
tissues.  
Here, the light source is split between that entering the eye and a reference path.  The 
light reflected back from the two paths forms an interference pattern when the distance 
in the two paths matches to within the coherence length of the light source.  Due to the 
coherent detection, OCT allows measurements of weakly reflecting retinal layers. This 
may be measured in the Time domain (taking into account the position of a reference 
mirror or optical delay line in the reference channel), or in the Spectral domain using a 
spectrometer or sweeping the light source wavelength and calculating the inverse 
Fourier transform as a function of wavelength. The high resolution of OCT makes it is 
possible to obtain images in the living eye that previously were only possible by 
removing the tissue and examining it under the microscope (Huang D et al, 1991; Gong 
J et al., 2016). 
OCT is very useful in the assessment and diagnosis of dry and wet AMD. It enables 
clinician to evaluate and measure response to treatment of wet AMD. The high-
resolution images have reduced the necessity to perform invasive diagnostic tests like 
FA and ICG (Gong J et al., 2016). 
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Figure 1.4: Neovascular AMD as seen in (A) OCT B-scan (B) FA (C) ICG (D) 
OCTA (Figure adapted from Eandi CM et al 2017): (A) OCT B-scan shows a 
juxtafoveal hyper-reflective area and adjacent subretinal fluid, (B) FA shows a 
juxtafoveal CNV with well-defined borders, (C) ICG confirms the presence of 
the well-defined CNV, (D) OCTA demonstrates the capillary CNV with well-
defined borders 
 
Optical Coherence Tomography Angiography  
Optical coherence tomography angiography (OCTA) is a new imaging technology 
which allows for non-invasive visualization of normal and pathologic vascularization. 
OCTA allows for the visualization of both the inner and outer retinal vascular plexi, as 
well as the choriocapillaris layer, without the need for dye injection and provides a 
segmentation of the different layers using the en face OCT modality. This imaging 
technique detects erythrocyte movement by comparing sequential OCT B-scans at a 
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given cross section. OCT angiograms are co-registered with OCT B-scans from the 
same area, allowing for simultaneous visualization of structure and blood flow (Eandi 
CM et al., 2017). 
 
6. Treatment of AMD 
 
Dry AMD 
The dry type of AMD affects approximately 80- 90% of individuals with AMD. Initial 
stages of the disease are asymptomatic. It can cause gradual deterioration of vision as 
disease progresses. Unfortunately, there is no treatment currently available for dry 
AMD. Several different treatment strategies are being investigated, including 
complement inhibition, neuroprotection, and visual cycle inhibitors. Recently, at the 
American Academy of Ophthalmology (AAO) 2017 Annual Meeting, researchers 
reported negative findings for two pivotal phase-3 clinical trials of Lampalizumab, 
exploring complement inhibition as a means of halting the progression of geographic 
atrophy. 
There is some evidence that antioxidants and high doses of vitamin A, C, E, the 
minerals zinc and copper, and the micronutrient lutein when taken together may help 
slow down the progression of dry AMD, particularly if AMD has already caused vision 
changes in one eye.  
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Age-Related Eye Disease Study (AREDS) was designed to gain better understanding of 
the natural history and the risk factors of age-related macular degeneration (AMD) and 
cataract, and to evaluate the effect of high doses of vitamin C, vitamin E, beta-carotene 
and zinc on the progression of AMD and cataract. The study showed that high levels of 
antioxidants and zinc significantly reduce the risk of advanced AMD and its associated 
vision loss (AREDS Research Group Report No. 9. 2001).  
Out of the 3640 enrolled participants in AREDS study, data was available from 3597 
participants to review the effect of interventions on visual acuity. In patients with 
extensive intermediate drusen, large drusen, or noncentral GA in one or both eyes, or 
advanced AMD or visual acuity <20/32 attributable to AMD in one eye (classified as 
category 3 and 4 patients), treatment with zinc alone or in combination with 
antioxidants reduced the risk of progression to advanced AMD. Compared with the 
placebo group, only those participants in Categories 3 and 4 assigned to antioxidants 
plus zinc had a statistically significant reduction in the odds of a 15-letter or greater 
visual acuity decrease (P=.008). Findings of AREDS suggest that the estimated 27% 
odds reduction in the visual acuity outcome for the combination arm may be the 
combined benefit of the zinc component (odds reduction of 17%) and the antioxidant 
component (odds reduction of 15%). The visual acuity benefit observed for the 
combination arm remains consistent for other, more severe, visual acuity outcomes, 
such as visual acuity worse than 20/100 or a decrease in visual acuity of 6 lines or more. 
These same nutrients had no significant effect on the development or progression 
of cataract (AREDS Research Group Report No. 9. 2001).  
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AREDS 2 studied the effect of omega-3 fatty acids, as well as the antioxidants lutein 
and zeaxanthin, which are in the same family of nutrients as beta-carotene. Researchers 
also substituted lutein and zeaxanthin for beta-carotene, which prior studies had 
associated with an increased risk of lung cancer in smokers. The study found that while 
omega-3 fatty acids had no effect on the formulation, lutein and zeaxanthin together 
appeared to be a safe and effective alternative to beta-carotene (AREDS2 Research 
Group, 2013).  
 
Wet AMD 
Wet AMD is responsible for severe visual loss if left untreated. Initially, verteporfin 
photodynamic therapy was introduced to treat classic or predominantly classic CNV. 
This was found to prevent severe visual loss in patients with wet AMD (Blinder KJ et 
al., 2003). In photodynamic therapy, a light-sensitive medicine called verteporfin 
(Visudyne; Novartis) is injected into the bloodstream, and collects in the abnormal 
blood vessels under the macula. Laser light is then shone into the eye, which activates 
the medicine and causes it to create blood clots that block the abnormal blood vessels. 
By sealing the leaky blood vessels, photodynamic therapy slows down the build-up of 
fluid under the retina. 
Vascular endothelial growth factor (VEGF) is widely considered the main growth factor 
leading to the increased angiogenesis causing choroidal neovascular membrane. The 
first breakthrough in anti-VEGF therapy for the treatment of wet AMD treatment was 
pegaptanib (Macugen; Eyetech Pharmaceuticals/Pfizer) in 2004 (Kourlas H and Schiller 
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DS, 2006). However, visual decline has been found to continue in AMD patients who 
were treated with pegaptanib. 
Bevacizumab (Avastin; Genentech), first used off-label in 2005 (Yoganathan P et al., 
2006), and Ranibizumab (Lucentis; Novartis (FDA approved in June 2006)), (Rosenfeld 
PJ et al., 2006; Brown, DM et al., 2009), are other two anti-VEGF agents with similar 
efficacy in treating wet AMD when injected monthly into the eye.  
The two pivotal phase III trials (ANCHOR and MARINA) investigated the benefits of 
Ranibizumab in the treatment of wet AMD. ‘Antibody for the Treatment of 
Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular 
Degeneration’ (ANCHOR) trial compared Ranibizumab with Verteporfin photodynamic 
therapy (PDT) in treating predominantly classic CNV. At 2 years, the visual acuity 
benefit from ranibizumab was statistically significant (P<0.0001 vs. PDT): 90.0% of 
ranibizumab-treated patients had lost <15 letters from baseline (vs. 65.7% of PDT 
patients); 34% to 41.0% had gained >15 letters (vs. 6.3% of PDT group) (Brown, DM et 
al., 2009) 
The ‘Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the 
Treatment of Neovascular Age-Related Macular Degeneration’ (MARINA) study 
investigated the response of neovascular AMD patients with minimally classic or occult 
CNVs to Ranibizumab (Rosenfeld PJ et al., 2006). After 24 months 90% of the 
Ranibizumab-treated patients had lost fewer than 15 letters compared with 53% in the 
control group. Moreover, 26.1% of patients receiving 0.3 mg Ranibizumab gained at 
least 15 letters of visual acuity versus only 3.8% in the sham-injected patients. 
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Bevacizumab, showed promising results in a published series for treating neovascular 
AMD with similar visual outcomes and reduction of retinal thickness, when compared 
with the licensed intravitreal Ranibizumab (IVR). However, Ranibizumab was noted to 
be more effective in reducing the lesion size (Comparison of Age-related Macular 
Degeneration Treatments Trials (CATT) Research Group; IVAN Study Investigators, 
2012). 
Aflibercept (VEGF Trap-eye, Eylea, (Bayer)) was approved in November 2011 by FDA 
for the treatment for wet AMD (Heier JS et al., 2012). The binding affinity and long 
half-life of this agent present the possibility of cost savings and decrease in frequency of 
use. 
The ‘VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD’ (VIEW 1 and 
VIEW 2) studies demonstrated that intravitreal Aflibercept, dosed every 2 months after 
three initial monthly doses, was non-inferior and clinically equivalent to monthly 
Ranibizumab injection. Furthermore, patients in the intravitreal Aflibercept (IVA) 8-
weekly group achieved visual and anatomical improvements similar to the IVR group 
with a mean of five fewer injections over 96 weeks (Heier JS et al., 2012). 
Late AMD is characterized by irreversible cell loss, initially of RPE cells and 
subsequently of neuroretinal and choroidal cells. da Cruz et al recently published results 
of phase 1 study of successful delivery and survival of the Retinal Pigment Epithelial 
(RPE) patch on two patients with advanced wet macular degeneration. This work 
supports the feasibility and safety of human embryonic stem cell (hESC)- RPE patch 
transplantation as a regenerative strategy for AMD (da Cruz L et al., 2018). 
 
32 | P a g e  
 
B. METABOLOMICS: AN OVERVIEW 
 
Eye diseases are often multifactorial in origin, with several environmental and genetic 
risk factors at play. In most cases, pathogenetic mechanisms remain poorly understood. 
‘Omics’, with the use of DNA sequencing, mass spectrometry and bioinformatic 
analyses, attempts large-scale characterization and quantitation of biological molecules 
in whole systems (Lauwen S et al, 2017). This is particularly useful in human diseases 
where the aetiopathology is poorly understood and can provide novel insights to 
enhance our understanding of disease processes. 
Omics technique (Figure 1.4) include: 
• Genomics 
- Genome wide association studies (GWAS) (Bush WS and Moore JH, 
2012).: DNA samples of large case-control cohorts are genotyped using 
microarrays, targeting a large number of single nucleotide polymorphisms 
(SNPs) distributed over the genome. Subsequent statistical analysis 
determines, for each variant, whether the frequency is significantly different 
in cases compared to controls. This helps to detect genetic variants that are 
mostly common in the population. To identify rare variants, whole exome 
sequencing (WES), or whole genome sequencing (WGS) is more effective. 
WES identifies and sequences the DNA that codes for the proteins (exons) 
while WGS determines the complete DNA sequence of the genome at a 
single time (Fritsche LG, Fariss RN, 2014). 
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• Epigenomics  
- Refers to the analysis of functionally relevant changes to the genome that do 
not involve a change in the DNA sequence, such as DNA methylation and 
different types of histone modifications (Dirks RA et al., 2016). 
• Transcriptomics  
- Refers to the analysis of all the mRNA molecules transcribed from the 
genome, either using microarrays or RNA sequencing (RNAseq). RNAseq 
is preferred as it uses next generation sequencing (NGS) to identify the 
presence and quantify RNA in a biologic sample (Mantione KJ et al., 2014). 
• Proteomics  
- Refers to the study of proteins and their modifications. 
• Metabolomics  
- Refers to the study of types and quantities of various metabolites in 
biological fluids or tissues. It is a powerful discipline that attempts to 
characterize the complex time-dependent metabolite profiles within 
biofluids and tissues.  
 




Figure 1.5: Overview of the different layers within a biological system 
contributing to multifactorial diseases and their relation to each other.  
(Figure adapted from Lauwen S et al., 2017) 
 
While all of these approaches can offer novel insights into the genetics and/or 
aetiopathology of human disease, metabolomics has some advantages since it measures 
products derived from the function of genes and proteins and thus gives an overall 
assessment of the potential changes suggested by gene and protein expression profiling. 
In other words, it analyses the overall metabolic activity of an organism, and so 
metabolomics and its application to diseases will be described further. 
 
Metabolomic analysis 
Metabolism underpins the function of all cells and tissues and the metabolites used and 
produced by particular cell types reflect their function. A metabolic profile of a tissue or 
biofluid can be influenced by genetic factors, age, lifestyle, environmental factors, 
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nutritional status, drugs and metabolites from gut microflora. Once the noise from the 
day-to-day variation is isolated, it gives a stable, natural and invariable profile of that 
subject. Assfalg et al in a study of healthy donors generated metabolic fingerprints using 
one-dimensional 1H-Nuclear Magnetic Resonance (NMR) spectroscopy that identified 
strong characteristics of each donor sample making it possible to identify individual 
donors from their metabolic profile with 100% probability (Assfalg M et al., 2008). 
This demonstrates the ability of the approach to discriminate specific phenotypes and so 
suggests that perturbation of these in disease might be identifiable. Although this study 
used NMR spectroscopy to derive the metabolic profiles, these can also be obtained by 
other analytical techniques, in particular, mass spectrometry. 
 
NMR spectroscopy and Mass spectrometry 
The nuclear magnetic resonance phenomenon in solids and liquids was discovered by 
Bloch and Purcell in 1945. When radiofrequency energy is applied to nuclei within a 
sample, the energy can be absorbed and re-emitted, and the frequency of the transmitted 
signal reflects the molecular environment of the nuclei. NMR spectra arise from 
transitions made by atomic nuclei between different energy states. When pulses of 
electromagnetic radiation are applied at frequencies that precisely match energy gaps, a 
stronger, coherent signal is emitted by nuclei within the sample and these emitted 
signals allow identification of molecular structures. Nuclei in different chemical 
environments (e.g. the different 1H nuclei in a protein) will resonate at different 
frequencies, producing a plot of intensity against resonance frequency known as a 1D 
NMR spectrum. The 2D 15N-HSQC (heteronuclear single-quantum coherence) 
spectrum, shows a signal for each covalently bonded 1H-15N group. Each signal in this 
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spectrum has an intensity and two chemical shifts (one for the 1H and another for 
the 15N nucleus) and the spectrum plotted provides a topographic map. Further analysis 
allows identification of the molecular structures within a sample (Beckonert O et al., 
2007).  
In mass spectrometry, molecular structure is probed by bombarding molecules with a 
beam of high energy electrons, causing ionization of proteins or metabolites, followed 
by mass spectrometric analysis of the mass/charge (m/z) ratios of a peptide or 
metabolite. The metabolite can then be identified from its precise mass and charge from 
public databases (Mishur R et al., 2012; Bowrey H et al., 2016). 
While mass spectrometry is a chemical process, NMR spectroscopy is a physical 
process. Mass spectrometry is highly specific and sensitive, however, it measures mass 
and charge, so it cannot always delineate between two molecules of similar mass. NMR 
spectroscopy is somewhat less sensitive but the signal derived is directly related to the 
concentration of a molecule in a sample and it can identify molecules by their structure. 
Thus, each approach has advantages and disadvantages. 
 
Metabolomics in systemic diseases 
Metabolomic analysis of biofluids has been applied to successfully discriminate patients 
in terms of prognosis and diagnosis of human diseases such as diabetes, high blood 
pressure and cancer. Identifying metabolomic profiles may also help to predict a 
response to treatment.   
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Changes have been noted in the urinary metabolic profile of those patients with 
rheumatoid (RA) and psoriatic arthritis (PsA) who received anti-TNF therapy; different 
metabolic profiles were also observed with different medications. Baseline urine 
metabolic profiles histamine, glutamine, xanthurenic acid, and ethanolamine 
discriminated between RA patients who did or did not have a good response to anti-
TNF therapy with a sensitivity of 88.9% and a specificity of 85.7%. In both RA and 
PsA, urinary metabolic profiles changed between baseline and 12 weeks of anti-TNF 
therapy. Within the responders, urinary metabolite changes distinguished between 
etanercept and infliximab treatment. These authors suggested that TNF-driven cachexia 
was driving the production of muscle degradation products in those patients who 
responded to anti-TNF, thus providing and explanation for the predictive value of the 
metabolite profiles (Kapoor SR et al., 2013). 
The serum metabolic profile of patients with established rheumatoid arthritis was found 
to be different from that of healthy controls. Inflammation appeared to be driving these 
differences since the researchers were able to stratify patients according to the level of 
inflammation, with the metabolic profile correlating with their C-reactive protein levels 
(Young S et al., 2013). An increased concentration of metabolites such as low-density 
lipoprotein lipids, lactate, glucose, taurine, acetylglycine, and methylguanidine seen in 
RA patients correlated well with the measured CRP level. Another metabolite of interest 
was 3-hydroxybutyrate which was elevated in the patients with established RA 
compared to controls, suggesting an increased level of lipolysis in RA patients. A 
noticeable change was low level of lipid signals in patients with established RA. Indeed, 
changes in lipid levels have been noted previously in patients in the period before they 
developed full RA suggesting that the lipid changes may be important in the 
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development of the disease (Myasoedova E et al., 2010; Kapoor SR et al., 2013; Young 
SP et al., 2013). 
In a study of coronary heart disease, analysis of serum NMR spectra successfully 
differentiated between varying degrees of coronary artery stenosis that ordinary blood 
tests failed to recognise. The change in the circulating level of metabolites from 
immediately before exercise to immediately after exercise was calculated separately in 
cases (patients with inducible ischaemia) and controls (with no ischaemia). Concordant 
decrease in levels of lactate, and increase in levels of hypoxanthine, inosine and alanine 
was noted in both cases and controls. However, γ-aminobutyric acid, oxaloacetate, 
citrulline and argininosuccinate was noted to decrease in cases but not in controls. 
Further, oxaloacetate and citrulline levels correlated with the extension of perfusion 
defect. These metabolites belonging to the citric acid pathway showed statistically 
significant relation to the probability of ischemia. The citric acid cycle plays a central 
role in oxidative phosphorylation in the myocardium. In normal cardiomyocytes, there 
is a constant rate of mitochondrial efflux of citric acid cycle intermediates. This stresses 
the need for preservation of citric acid cycle intermediates to defend ATP production in 
acute ischaemia (Sabatine M, 2005).  
In NMR spectroscopy of cerebrospinal fluid (CSF) (Sinclair et al., 2009), patients with 
multiple sclerosis (MS) showed higher CSF levels of lactate, creatinine and fructose, 
compared to control patients. Concentration of α-hydroxyisobutyrate, a partial 
degradation product of branched chain amino acids, was also found to be high in MS 
patients. This is thought to be secondary to respiratory-chain deficiency, leading to 
impaired oxidation of NADH.  In a second study (Reinke et al), mean levels of choline, 
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myo-inositol and threonate were found to be increased in CSF, whereas 3-
hydroxybutyrate, citrate, phenylalanine, 2-hydroxyisovalerate and mannose were 
decreased in MS-derived CSF (p<0.05), suggesting alterations to energy and 
phospholipid metabolism. 
Patients with idiopathic intracranial hypertension (IIH) showed high levels of lactate, 
glucose, acetate, 3-hydroxybutyrate and oxaloacetate, and low levels of citrate, urea, 
creatinine and 3-hydroxy isovalerate in their CSF. Predominant lactate peaks suggest a 
possible inflammatory aetiology in IIH. It could also indicate anaerobic metabolism due 
to reduced blood supply resulting from compressed vasculature in IIH patients. The 
interpretation of CSF metabolites is complex as the metabolites may reflect systemic 
metabolism and subsequent transfer across the blood brain barrier or local CNS 
generation (Sinclair et al., 2010). 
 
Metabolomics and the eye  
In preliminary experiments, research team at the University of Birmingham investigated 
the use of NMR-based metabolomics to compare serum samples from healthy elderly 
and young individuals and showed that a clear stratification is possible. In a longitudinal 
study of metabolites in the blood and urine of healthy controls, little variability was 
noted between subjects and study days, suggesting that metabolomic data have 
acceptable variability and may highlight biomarkers of disease (Lenz EM et al., 2003).  
Metabolomics has been employed to explore the various pathways involved in the 
pathogenesis of specific ocular conditions. Some of the pathways thus identified include 
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pathways of urea metabolism, inflammation, and lipid metabolism; these are some of 
the pathways explored in the pathogenesis of AMD. 
• Uveitis  
The metabolomic profiling of samples of vitreous humour from patients with ocular 
inflammatory conditions demonstrated its ability to differentiate between lens-induced 
uveitis (LIU) and chronic uveitis (CU), with a sensitivity of 78% and specificity of 
85%, with urea, oxaloacetate and glucose all being raised in LIU samples compared to 
CU samples. Both urea and oxaloacetate are part of urea cycle, urea being produced 
during conversion of arginine to ornithine.  This process is prominent in activated 
macrophages and endothelial cells, suggesting more active inflammation in the LIU 
patients (Young SP et al., 2009). 
• Glaucoma  
In primary open angle glaucoma (POAG) metabolic analysis of sera showed altered 
lipid metabolism, separating them from control samples.  The metabolites palmitoyl 
carnitine, sphingolipids, vitamin D-related compounds, and steroid precursors were 
identified. These metabolites suggested involvement of galactose metabolism, fructose 
and mannose metabolism, and steroid hormone biosynthesis pathways in the 
pathogenesis of POAG (Burgess L et al., 2015). 
• Myopia  
The heritability for refractive error has been calculated to be larger than 50%. GWAS 
and WES studies performed in families have suggested some of the possible myopia-
associated pathways; however, still only 3.4% of all genetic variability of refractive 
error can be explained. Metabolomic analysis identified 29 metabolites in aqueous 
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humour of myopes compared to controls. More than half of the changed metabolites 
were highly and positively associated, giving insight into important roles of pathways 
involved in the metabolism of these metabolites in relation to high myopia. Among the 
metabolites, four amino acids glutamine, N-alpha-acetyl-L-ornithine, nicotinoylglycine, 
and o-hydroxyhippuric acid were significantly increased. This indicates that metabolism 
of amino acids played a vital role in the development of high myopia. Glutamine 1 was 
reported to be associated with the generation of reactive oxygen species (ROS), which 
may indicate an increased oxidative stress in patients with high myopia (Ji Yet al., 
2017).  
• Dry eye syndrome 
Analysis of reflex tears from patients with dry eye disorders using 1H NMR 
spectroscopy showed different metabolites in those with dry eyes compared to controls. 
The most abundant molecules in the control tears were glycoprotein, lipids, cholesterol, 
leucine, glycerol, and glutamate.  The discriminating analysis of the dry eye syndrome 
group (DESG) revealed a significant increase in glucose and lactate, whereas formate 
and N-acetylglucosamine noticeably decreased in the moderate DESG compared to the 
mild DESG. The presence of lactate in human fluids is a consequence of anaerobic and 
aerobic metabolism of glucose. It also indicates a deficiency in the mitochondrial 
respiratory chain arising from the oxidative stress, causing decreased oxygenation and 
increased lactate production (Galbis-Estrada C et al., 2015).  
Further analysis following administration of antioxidant and essential polyunsaturated 
fatty acids supplements in DESG showed difference in metabolites before and after 
supplementation. H cholesterol, N-acetylglucosamine, glutamate, amino-n-butyrate, 
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choline, glucose, and formate were detected before supplementation while 
choline/acetylcholine were seen in samples tested after supplementation (Galbis-Estrada 
C et al., 2015).  
In another metabolome-wide association study of dry eye syndrome patients, dryness 
and irritation symptoms were found to be particularly strongly associated with 
decreased androgen steroid metabolites, especially epiandrosterone sulfate, further 
strengthening the hypothesis on the links between androgen and ocular surface diseases 
(Vehof J et al., 2017). 
• Diabetic eye disease 
Diabetes-induced corneal pathologies are known to delay corneal wound healing. 
Researchers studied the effects of diabetes on extracellular matrix, lipid transport, and 
cellular metabolism by defining the entire metabolome and lipidome of Type 1 and 
Type 2 human diabetic corneal stroma. Metabolomics analysis identified elevated 
tryptophan metabolites, independent of glucose metabolism, which correlated with 
upregulation of the Kynurenine pathway in diabetic corneas. A significant upregulation 
of novel biomarkers aminoadipic acid, D,L-pipecolic acid, and dihydroorotate was also 
noted, thus  linking aberrant tryptophan metabolism to end-stage pathologies associated 
with diabetes indicating the potential of the Kynurenine pathway as a therapeutic target 
for inhibiting diabetes-associated defects in the eye (Priyadarsini S et al., 2016) . 
In another study, plasma metabolites were identified that distinguished patients with 
diabetes and retinopathy from those without retinopathy. Two novel biomarkers were 
identified, 2-Deoxyribonic acid and 3,4-dihydroxybutyric acid. The researchers also 
identified pentose phosphate pathway as a key metabolic dysregulation associated with 
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DR, demonstrating the involvement of oxidative stress in disease pathogenesis (Chen L 
et al., 2016).  
• Leber's hereditary optic neuropathy 
In a study of one of the commonest mitochondrial DNA-related disease, Leber's 
hereditary optic neuropathy, metabolomics identified thirty-eight metabolites: decreased 
concentrations of all proteinogenic amino acids, spermidine, putrescine, isovaleryl-
carnitine, propionyl-carnitine and five sphingomyelin species, together with increased 
concentrations of 10 phosphatidylcholine species. This suggested an involvement of the 
endoplasmic reticulum. All these changes could be reversed by the endoplasmic 
reticulum stress inhibitor, tauroursodeoxycholic acid (TUDCA) (Chao de la Barca JM et 
al., 2016). 
• Macular degeneration 
Metabolomics is also being employed to understand the pathways involved in age 
related macular degeneration (AMD). Initial studies of sera with mass spectrometry and 
then with NMR spectroscopy have shown promising results in separating AMD patients 
from controls. The metabolites identified included di- and tripeptides, covalently 
modified amino acids, bile acids, and vitamin D-related metabolites. The pathway 
analysis has shown broader changes in tyrosine metabolism, sulphur amino acid 
metabolism, and amino acids related to urea metabolism (Osborn M et al., 2013; Laíns I 
et al., 2017). 
Previous works assessing the metabolite profile of patients with systemic and ocular 
diseases showed a strong segregation of different disease groups and demonstrated a 
relationship between serum markers and the metabolite profile. It seems that the 
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multiplexed analysis inherent to metabolomics, which considers all metabolite signals 
regardless of whether they have been specifically identified, is able to provide 
information not available by other means. This strongly suggests that metabolomics 
may provide important insights into the role of changing metabolites in the AMD 
pathological process. This provides the basis of our research hypothesis that the 
metabolic characteristics of patients with dry and wet AMD are different and can 
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Methods  
Ethics approval was obtained from NRES committee North East- Sunderland (REC 
reference number- 11/NE/0162). 
Patients with dry and wet macular degeneration were recruited from the medical retina 
clinics at Royal Victoria Infirmary, Newcastle upon Tyne. 104 consecutive patients who 
had AMD confirmed by clinical evaluation and investigations were included in the 
study. Informed consent was obtained. Detailed history including duration of symptoms, 
smoking habits, general medical history and systemic treatment, if any, were noted. 
Patients with diabetes mellitus were not excluded, and BMI was not measured for the 
participants. Blood and urine samples were collected from a total of 104 patients; 73 
patients had wet and 31 had dry macular degeneration. Patients in both groups were 
matched in every respect including age, sex and systemic illnesses. Being matched in all 
respects, except the type of macular degeneration, we inferred that any changes we may 
see will be due to the type of the disease and as such a healthy control group was not 
deemed necessary.  
Inclusion criteria 
Patients over 55 years of age with confirmed diagnosis of age related macular 
degeneration. 
Exclusion criteria  
Patients who were unable to give consent and those with known history of cancer or 
severe inflammatory disease, e.g. rheumatoid arthritis, were excluded from the study.  
 
 
47 | P a g e  
 
Sample collection 
 20ml of a “random” urine sample (i.e. the timing of the collection was not controlled) 
provided by the patient was collected into a universal container and was frozen 
immediately in a -80 oC freezer. 
Non-fasting blood was collected from patients in a red top vacutainer serum tube (with 
clot accelerator). The tube was left to stand for an hour in a refrigerator, before 
centrifugation in the cold at 3000 rpm for 10 minutes. Then, 2 ml serum was transferred 
into a cryovial using a Pasteur pipette, marked with the patient’s ID and date, then 
immediately frozen in a -80 oC freezer. The samples were transported on dry ice to the 
academic unit at University of Birmingham. The samples were then stored at -80 oC in a 
freezer in the Institute of Biomedical Research, at University of Birmingham until 
analysis.  
 
Laboratory analysis: sample preparation and analysis 
After thawing, serum was centrifuged for 5 mins at 15,000 x g(av) and an aliquot (200 
microL) was removed and filtered by centrifuging at 10,000 x g(av) for 10 mins at 4 oC 
through a centrifugal 3kD MW cut-off filter to remove proteins. The filters had been 
previously washed 6x by centrifuging through warm water (0.5ml at 3,000 x g(av)) to 
remove preservative glycerol. The protein-free filtrate was made with 10% in D2O, 20mM 
phosphate 0.5mM TMSP and pH 7.00 by the addition of a 4x concentrated “NMR buffer”.  
Urine samples were defrosted on ice, filtered to remove any cells or bacteria. 500 microL 
of the sample was transferred into a fresh microcentrifuge tube, and centrifuged at high 
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speed (13,000xg) for 5 minutes.  Then D20, phosphate buffer and TMSP was added NMR 
standard. The filtrate was made 10% in D2O, 20mM phosphate 0.5mM TMSP and pH 
7.00 by the addition of the 4x NMR buffer. The pH of urine can be variable and so each 
sample was carefully taken to pH 7.00 by the addition of NaOH or HCl. The samples 
were left for 30 mins at room temperature and the pH adjusted again to 7.00. 
Samples of urine or serum (50 microL) were transferred to small conical glass vials, 
capped and frozen at -80 oC until analysis. For analysis, samples were defrosted and a 
sample (35 microL) was transferred to a 1.7mm glass NMR tube using an Anachem 
robotic sample handler. The tubes were capped, wiped and placed in rack in the 
spectrometer. 
One-dimensional 1H spectra were acquired using a NOESY sequence with water 
saturation with pre-sat on a Bruker DRX 600 MHz NMR spectrometer equipped with a 
1.7 mm cryoprobe. 2D JRes spectra also was acquired to aid metabolite identification by 
comparison with the Birmingham Metabolite Library.  
NMR spectroscopy requires samples to contain concentrations of target molecules in the 
high micro molar range for it to be detectable due to its low sensitivity. However, the 
cryoprobe in the NMR spectroscope enabled us to minimize electronic noise and 
maximize its sensitivity to the small NMR signals from dilute samples. This made it 
possible to acquire well-resolved spectra from the samples in a short span of time.  
Spectra were segmented into 0.005 ppm (2.5 Hz) chemical shift ‘bins’ between 0.2 and 
10.0 ppm, the spectral area within each bin integrated. This turns each spectrum from a 
continuous analogue signal into an array of data points. Each spectrum is segmented into 
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approximately 2,000 regions and the area under each segment integrated. The total 
spectrum of each sample is normalised. The binned data describing each spectrum is 
compiled into a matrix with each row representing an individual sample. The spectra 
contain both dominant and less intense peaks. Once log-transformed, the small and large 
peaks will have equal weighting. 
 
Multivariate analysis of samples 
Principal component analysis (PCA) and partial least squares discriminant analysis 
(PLS-DA) of the processed data were conducted using PLS Toolbox (Eigenvector 
Research) within Matlab.    
One of the difficulties inherent in multivariate statistics is visualizing data that has many 
variables. In data sets with many variables, groups of variables often move together. 
The multiple variables are simplified by replacing a group of variables with a single 
new variable. PCA is the most widely used multivariate analysis method for achieving 
this simplification. The method generates a new set of variables, called principal 
components (PC). Each principal component is a linear combination of the original 
variables. All the principal components are orthogonal to each other, so there is no 
redundant information. The principal components as a whole form an orthogonal basis 
for the space of the data. PCA of the transformed datasets assesses the covariance 
around the mean of the data in each region of the spectrum and assesses how they relate 
to each other. The first principal component is a single axis in space. Each observation 
projected on that axis form a new variable. And the variance of this variable is the 
maximum among all possible choices of the first axis. The second principal component 
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is another axis in space, perpendicular to the first. Projecting the observations on this 
axis generates another new variable. The variance of this variable is the maximum 
among all possible choices of this second axis. The PCs describe the direction of the 
greatest variation in the data, with 2 or 3 PCs explaining the major covariance trends 
within the data. In effect, PCA identifies the most highly variable metabolites in the 
NMR spectra (Cho H et al., 2008). 
The separation seen in the PCA is further enhanced in the clustering analysis, PLS-DA. 
While PCA is an unsupervised model, PLS-DA is a supervised analysis. This technique 
builds a model which identifies the metabolites which vary between diagnostic groups, 
potentially enabling the identification of diagnostic groups.  
A venetian blind is used to cross validate the PLS-DA model, a method which re-
assigns randomly selected spectral data to the PLS-DA model to determine the 
sensitivity and specificity of the model in correctly assigning diagnostic groups. This 
helps to determine the accuracy of the model in correctly assigning class membership. 
PLS-DA allows a predictive model to be generated and the validated model segregated 
the dry and wet AMD with a sensitivity and selectivity of 73.3% and 87.5%.  
 
Statistical analysis 
Multivariate analysis methods help to identify biologically relevant spectral features for 
further targeted analyses. The two methods commonly used are principal component 
analysis (PCA) and partial least squares projection to latent structures (PLS). 
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The strength of metabolomic analysis is not based strictly on numbers, as it is the total 
profile that is being measured. There will be differences between normal individuals 
based on lifestyle, but the disease specific profile stands out from this noise, as has been 
shown in previous studies (Assfalg et al., 2008; Young S et al., 2009 and 2013).  
The techniques utilised were (a) Principal components analysis (PCA) using the PLS 
Toolbox (version 5.8) (Eigenvector Research) in Matlab (release 2010a) (Mathworks), 
and (b) Partial least square discriminant analysis (PLS-DA) using PLS Toolbox (details 
given above). 
Principal Components Analysis (PCA) is an unsupervised method that facilitate the 
extraction of implicit patterns and elicit the natural groupings of the spectral dataset 
without prior information about the sample class (Jensen et al., 2004; Beckonert et al., 
2003). The PCA helps to arrive at a linear transformation preserving the variance in the 
original data as possible. The unsupervised nature of the PCA algorithm reveals group 
structure when ‘within-group’ variation is sufficiently less than ‘between-group’ 
variation. The results of PCA analyses was used to formulate an initial biological 
conclusion, which was then verified with the supervised forms of discriminant analysis 
such as Partial Least Squares (PLS-DA) that rely on the class membership of each 
observation (Cho H et al., 2008). 
PLS-DA is used to predict a continuous or discrete/categorical variable. It helps to 
optimise separation between different groups of samples, by linking two data matrices X 
(raw data) and Y (groups, class membership etc.). Orthogonal signal correction PLS-DA 
or O-PLS-DA is an extension of PLS-DA which seeks to maximize the explained variance 
between groups in a single dimension or the first latent variable (LV), and separate the 
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within group variance (orthogonal to classification goal) into orthogonal LVs (Wold S et 
al., 1998). Therefore, orthogonal PLS-DA compared to predictive analysis utilises 
information related to structured variance removing residual variance or noise. 
Orthogonal data is therefore based on many fewer variables than in predictive analysis 
(Johnson C et al., 2016).  
The PCA helps to arrive at a linear transformation preserving the variance in the original 
data as possible. The unsupervised nature of the PCA algorithm reveals group structure 
when ‘within-group’ variation is sufficiently less than ‘between-group’ variation. The 
results of PCA analyses was used to formulate an initial biological conclusion, which was 
then verified with the supervised forms of discriminant analysis such as Partial Least 
Squares (PLS-DA) that rely on the class membership of each observation. Once 
classification is done in PLS-DA, further classification is performed in the SIMCA (Soft 
Independent Modelling of Class Analogy). 
The quantitative NMR spectral profiling using Human Metabolome Database, 
BAYESIL and Chenomx was utilised to identify the metabolites. 
The Human Metabolome Database (HMDB) is an electronic database containing 
detailed information about small molecule metabolites found in the human body. The 
database contains or link three kinds of data: 1) chemical data, 2) clinical data, and 3) 
molecular biology/biochemistry data. The database contains 74,462 metabolite entries 
including both water-soluble and lipid soluble metabolites as well as metabolites that 
would be regarded as either abundant (> 1 uM) or relatively rare (< 1 nM). Additionally, 
5,701 protein sequences are linked to these metabolite entries (Wishart D et al., 2007; 
2013). 
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BAYESIL is a web system that automatically identifies and quantifies metabolites using 
1D 1H NMR spectra of ultra-filtered plasma, serum or cerebrospinal fluid. It can 
autonomously find the concentration of NMR-detectable metabolites accurately (~ 90% 
correct identification and ~ 10% quantification error), in less than 5 minutes on a single 
CPU (Ravanbakhsh S et al., 2015).  
CHENOMX on the other hand, offers a method of simplifying the measurement of the 
concentration of biological mixture components as measured by NMR instruments. The 
method is based on software and an extensive spectral signature library of relevant 
metabolites. It consists of both theoretical and empirical data within a model which 
adjusts to the NMR field strength and sample conditions to closely match that of the 
experiment spectrum. Then the software, through a combination of automated and 
supervised operation, uses the models to de-convolute the spectral signatures of the 
various components in the mixture being measured. Overlapping spectral areas are 
simplified by the subtraction of the identified peaks of known components from the 
spectrum as they are fitted into the spectrum. Then the ‘left over’ spectral peaks are 
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A total of 104 consecutive patients, aged between 55 and 94 years, who attended 
medical retina clinics and met the inclusion criteria were enrolled into the study. All 104 
patients provided blood samples; random urine sample was given by 103 patients. 
Fourteen patients with wet AMD and 4 patients with Dry AMD were diabetic. Ethnicity 
data was not collected. The demographic detail of our sample group is given in Table 
3.1 below. 
Total number of patients 104 
Patients with Dry AMD 31 
Dry AMD patients with GA 8 
Patients with Wet AMD 73 
Wet AMD patients on anti VEGF treatment (Ranibizumab) 
45 
Serum samples 104 
Urine samples 103 
 Wet AMD Dry AMD 
Males 27 11 
Females 46 20 
Smokers 31 4 
Non-smokers 42 27 
 
Table 3.1: Demographic details of patients in our cohort 
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Analysis of all serum samples 
All 104 serum samples were processed and analysed using NMR spectroscopy. The 
NMR spectra were then further analysed using human metabolome database (HMDB), 
Bayesil spectral analysis (Bayesil.ca) and Chenomx to identify the significant individual 
metabolites. 
The samples were first analysed using PCA to identify any trends or clustering in the 
standardised data, and the maximum variation of the data. PC1 (30.02%) showed 
clustering either side of median, while PC2 (19.34%) showed a potential separation of 
two populations within the cohort of samples. There were a couple of outliers that could 
not be explained by the demographic data (Figure 3.1) and may have arisen from 
technical issues with the spectra.  
 
Figure 3.1: Principal Component Analysis of all serum samples (N= 104) 
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When the samples were analysed on the basis of dry or wet AMD diagnosis, PCA 
analysis showed no obvious clustering in either component in serum samples from 
patients with dry (dark blue) and wet (light blue) in each quadrant (Figure 3.2).  
 
Figure 3.2: Principal Component Analysis of all serum samples (N= 104) 
showing wet and dry AMD samples 
 
To further investigate any segregation of the data, a supervised PLS-DA analysis of the 
NMR spectra of the serum samples was done and this showed clustering of the majority 
of samples of patients with wet AMD (Figures 3.3 and 3.4), and this difference was 
augmented after orthogonal signal correction was applied (Figure 3.4). The cross-
validated model segregated the dry and the wet AMD with a sensitivity and specificity 
of 73.3% and 87.5% respectively. However, it also showed overlap of samples of 
patients with wet and dry AMD samples. 
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Figure 3.3: Partial Least Squares Discriminant Analysis (PLS-DA) of all serum 
samples (N= 104) showing clustering and separation of wet and dry AMD 
samples 
 
Figure 3.4: Partial Least Squares Discriminant Analysis (PLS-DA) of all serum 
samples (N= 104) after orthogonal signal correction was applied showing more 
clustering and separation of wet and dry AMD samples 
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Metabolites in wet and dry AMD serum 
The loading plots from the PLSDA models identified which regions of the NMR spectra 
were contributing to the discrimination between the wet and dry sample groups. These 
loading plots were further analysed using human metabolome database (HMDB), 
Bayesil spectral analysis (Bayesil.ca) and the Chenomx library on NMR spectra, to 
identify significant individual metabolites associated with such regions of the spectra. 
The metabolites identified in the wet AMD serum samples which dominated in the 
loading plot indicated increases in lactate, xanthine, gallic acid, pyridoxal, glycine and 
succinate, while the dry AMD sample showed increases in arginine, methyl guanine, 2,5 
dimethyl furan, uracil, gallic acid, succinic acid and ornithine (Fig 3.5, 3.6; Table 3. 2). 
 
Figure 3.5: NMR spectra of serum samples showing various metabolite peaks in 
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Wet AMD Dry AMD 
Lactate Arginine 
Xanthine Methyl guanine 
Gallic acid Gallic acid 
Pyridoxal Uracil 
Glycine 2,5 dimethyl furan 
Succinate Succinic acid 
 Ornithine 
Table 3.2: List of metabolites which showed an increase in serum analysis of wet and 
dry AMD patients. 
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Lactate and succinate are increased in inflammatory sites where cells switch ATP 
production from oxidative phosphorylation to glycolysis regardless of oxygen levels. 
Succinate has been shown to increase IL-1 stabilization of the enzyme hypoxia-
inducible factor-1 particularly in myeloid cells such as macrophages (Tannahill et al., 
2013). The metabolites data is supported by an increase in macrophages in human retina 
with AMD compared to aged healthy controls (McLeod et al., 2016). Moreover, these 
cells are more active than cells from controls. Increased levels of IL-1 have also been 
reported in the vitreous of patients with AMD (Lechner et al., 2017; Zhao et al., 2015).  
Xanthine is a metabolite in the pathway that converts ATP to uric acid via adenosine 
and hypoxanthine. Serum uric acid levels have been associated with neovascular AMD 
in a Malaysian cohort of patients (Subramani et al., 2010). However, this was not 
confirmed in a European cohort, although there were inverse correlations with 
antioxidants (superoxide dismutase) and cytokines (IL-6) in patients with wet AMD 
(Colak E et al., 2017). 
In patients with dry AMD, arginine and ornithine are components of the urea cycle that 
converts toxic ammonia to urea for excretion. The urea cycle has previously been 
associated with AMD in a liquid chromatography mass spectrometry analysis of plasma 
samples from patients with neovascular AMD (Osborn M et al., 2013). 
2, 5- dimethylfuran has been identified as one of the components of cigar smoke and 
blood concentration can be used as a biomarker for smoking. As stated, smoking is a 
risk factor for AMD but there have been no previous association of 2,5 dimethyl furan 
and AMD. 
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Taken together, metabolomic analysis of serum samples does not show any obviously 
different pathways involved in the two clinical forms of AMD. The increase in lactate 
and succinate in wet AMD suggests increased inflammation, possibly due to increased 
macrophage infiltration or increased activation of these cells. 
 
Analysis of all urine samples 
All 103 urine samples (one patient did not provide urine sample) were processed and 
analysed with NMR spectroscopy. 
The initial analysis of urine samples was done using PCA to identify any trends or 
clustering in the standardised data, and the maximum variation of the data. PC1 
(33.95%) showed clustering either side of median, while PC2 (10.31%) showed a 
potential separation of two populations within the cohort of samples. As seen in serum 
samples, there were a few outliers in the urine samples as well that could not be 
explained by the demographic data (Figure 3.7).  
When the samples were analysed on the basis of dry or wet AMD diagnosis, PCA 
analysis showed no obvious clustering in either component in urine samples from 
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Figure 3.7: Principal Component Analysis of all urine samples (N= 103) 
 
 
Figure 3.8: Principal Component Analysis of all urine samples (N= 103) showing 
wet and dry AMD samples 
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It was interesting to see that the PLS-DA analysis (Figures 3.9, 3.10) of the urine 
samples showed better clustering, separating the wet from the dry AMD samples, 
especially after orthogonal signal correction (Figure 3.10). The validated model 
segregated the dry and wet AMD with a sensitivity and specificity of 35.7% and 84.9% 
respectively. As noted in the pilot analysis, some of dry samples were noted to cluster 
with wet AMD samples, the significance of which needs to be explored further. 
 
 
Figure 3.9: Partial Least Squares Discriminant Analysis (PLS-DA) of all urine 
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Figure 3.10: Partial Least Squares Discriminant Analysis (PLS-DA) of all 
urine samples (N= 103) after orthogonal signal correction showing better 
clustering and separation of wet and dry samples 
 
Metabolites in wet and dry AMD urine 
In the urine samples from wet AMD patients, NMR spectroscopy showed peaks of 
alanine, carnitine, ornithine, citrate, trimethylamine-N-oxide, creatinine and hippurate, 
while samples from dry AMD showed peaks for cholate, succinate, syringic acid, 
isovaleroglycine, methanol, acetyl salicylate and N-phenyl acetyl glycine (Figure 3.11, 
3.12; Table 3.3). 
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Figure 3.11: NMR spectra of urine samples showing various metabolite peaks in 
wet and dry AMD patients 
 
Wet AMD Dry AMD 
Ornithine Cholate 
Alanine Succinate 
Citrate Syringic acid 
Trimethylamine-N-oxide Isovaleroglycine 
Creatinine Acetyl salicylate 
Hippurate N-phenyl acetyl glycine 
Table 3.3: List of metabolites which showed an increase in urinalysis of wet and 
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Figure 3.12: Chenomx analysis of the urine NMR spectrum: metabolite 
identified is hippurate 
 
The results show that certain metabolites such as ornithine and succinate are raised in 
urine from patients with AMD, although not necessarily in the same form of disease. 
Creatinine is formed in the muscle and degraded by the kidneys and is a normal 
component of urine. Raised levels have been reported in patients with type II diabetes 
with retinopathy and correlated with severity of ocular damage (Saxena et al., 2017).  
Syringic acid is a naturally occurring phenolic compound found in various plants such 
as mushrooms and in wine. It has an antioxidant activity and has been shown to inhibit 
osteoporosis in mice fed a high syringic diet (Tanaka et al., 2017). While inhibition of 
oxidative stress would be useful in mediating AMD, this metabolite is dietary and 
therefore its relevance is unclear. 
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Male and female: Serum 
We analysed the serum samples and found that the male and female samples separated 
well, with some female samples showing clustering within the male samples (Figure 
3.13). The validated model segregated the male and female patients with AMD with a 
sensitivity and specificity of 89.6% and 82.9% respectively. 
 
Figure 3.13: Partial Least Squares Discriminant Analysis (PLS-DA) of all serum 
samples (N= 104) showing male and female patients 
 
The analysis of the NMR spectra revealed the following metabolites: male samples 
showed peaks of succinate, syringic acid, gallic acid and creatinine; the female serum 
samples on the other hand showed peaks of thymine, syringic acid, glycolic acid, 
acetone and methyl malonic acid (Figure 3.14; Table 3.4). 
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Figure 3.14: NMR spectra of serum samples showing various metabolite peaks 





Syringic acid Syringic acid 
Gallic acid Glycolic acid 
Creatinine Acetone 
 Methyl malonic acid 
Table 3.4: List of metabolites which showed an increase in serum analysis of male 
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While there was good separation between sera from males and females, there was no 
specific pathway that distinguished between the two cohorts. Increased succinate could 
indicate more inflammation in males, while the increased creatinine may be indicative 
of greater muscle mass in males. Interestingly, similar to syringic acid, gallic acid is an 
antioxidant found in wine (Yildirim et al., 2004). 
 
Male and female: Urine 
Sub-analysis of the urine samples showed that it was possible to separate male and 
female urine sample reasonably, with some overlap (Figure 3.15). The validated model 
segregated the male and female patients with AMD with a sensitivity and specificity of 
65.1% and 64.6% respectively. 
 
Figure 3.15: Partial Least Squares Discriminant Analysis (PLS-DA) of all urine 
samples (N= 103) showing male and female patients 
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Both male and female samples showed creatinine, and 7-methyl adenine. In addition, 
the male urine showed peaks for succinate, citrate and purine while female samples 
showed ornithine and syringic acid (Figure 3.16; Table 3.5). 
 
Figure 3.16: NMR spectra of urine samples showing various metabolite peaks in 
male and female AMD patients 
 
Analysis of urine based on gender showed good discrimination, but similar to serum, 
there was no specific pathway that suggested a different pathogenesis related to gender. 
 
Separate analysis: male and female serum and urine: wet vs. dry AMD 
To investigate the role of gender in AMD, we further reassessed male and female serum 
and urine samples separately (Figures 3.17, 3.18, 3.19 and 3.20) from patients with wet 








7-methyl adenine 7-methyl adenine 
Succinate Ornithine 
Citrate Syringic acid 
Purine  
 
Table 3.5: List of metabolites which showed an increase in urinalysis of male and 
female AMD patients 
 
Female patients wet vs. dry AMD: serum samples 
 
Figure 3.17: Partial Least Squares Discriminant Analysis (PLS-DA) of serum 
samples of female patients (N= 66) showing separation of wet and dry AMD 
samples 
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 Male patients wet versus dry: serum samples 
 
Figure 3.18: Partial Least Squares Discriminant Analysis (PLS-DA) of serum samples 
of male patients (N= 38) showing separation of wet and dry AMD samples. 
 
Female patients wet versus dry: urine samples
 
Figure 3.19: Partial Least Squares Discriminant Analysis (PLS-DA) of urine samples 
of female patients (N= 65) showing separation of wet and dry AMD samples 
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Male patients wet versus dry: urine samples 
 
Figure 3.20: Partial Least Squares Discriminant Analysis (PLS-DA) of urine 
samples of male patients (N= 38) showing separation of wet and dry AMD samples 
 
It was interesting to note that the male urine samples separated the two disease groups 
better than the female samples (Figures 3.19, 3.20). 
 
Smokers versus non-smokers: Serum  
As smoking is a risk factor for AMD, we separately analysed serum samples to see if 
smoking induced any specific pathways related to the disease. The serum samples from 
non-smokers separated well from smokers in both female and male patients (Figure 3.21 
and 3.22). The validated model segregated the female smokers and non-smokers with 
AMD with a sensitivity and specificity of 77.4% and 78.1% respectively while for male 
smokers and non-smokers it was 77.4% and 83.6%. 
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Figure 3.21: Partial Least Squares Discriminant Analysis (PLS-DA) of serum 
samples of female patients (N= 66) showing separation of samples of smokers from 
non-smokers 
 
Figure 3.22:  Partial Least Squares Discriminant Analysis (PLS-DA) of serum 
samples of male patients (N= 38) showing separation of samples of smokers from 
non-smokers 
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Smokers versus non-smokers 
We sub-analysed male and female patients with wet AMD to see the influence of 
smoking. There were very few smokers in the dry AMD group, hence separate sub 
analysis for dry AMD patients was not possible. The samples from non-smokers 
separated well from smokers in both female and male patients with wet AMD (Figure 
3.23 and 3.24). 
 
Metabolic analysis of wet AMD serum: smokers versus non-smokers 
 
Figure 3.23: Partial Least Squares Discriminant Analysis (PLS-DA) of serum 
samples of female patients with wet AMD (N= 46) showing separation of 
samples of smokers from non-smokers. 
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Figure 3.24: Partial Least Squares Discriminant Analysis (PLS-DA) of serum 
samples of male patients with wet AMD (N= 27) showing separation of samples of 
smokers from non-smokers 
 
The NMR spectra of the subset of wet AMD serum sample sub-analysis identified the 
metabolites that were predominant in smokers and non-smokers (Figure 3.24).  
The metabolites that predominated in smokers were hypoxanthine, glycine, acetone, 1,2 
dibromoethane and -hydroxyisobutyric acid, while non-smokers had gallic acid, 
deoxyguanosine, pyruvate, succinate and citric acid (Figure 3.25; Table 3.6).  
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Figure 3.25: NMR spectra of serum samples showing various metabolite peaks in 
smokers and non-smokers 
 
Smokers Non-smokers 
Hypoxanthine Gallic acid 
Glycine Deoxyguanosine 
1,2 dibromoethane Pyruvate 
-hydroxy isobutyric acid Succinate 
 Citric acid 
 
Table 3.6: List of metabolites which showed an increase in serum analysis of 
smokers and non-smokers among AMD patients 
 
Smoker   
Non-smoker  
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In smokers, hypoxanthine was increased, suggesting that increased activity of the urea 
cycle seen in previous analyses may be driven by smoking. -hydroxybutyrate is 
derived from -ketobutyrate following amino acid catabolism and is metabolized to 
propionyl-CoA for entry into the Kreb’s cycle.   
Smokers versus non-smokers: Urine 
The urine samples from non-smokers separated well from smokers in both male and 
female patients with wet AMD (Figure 3.26, 3.27). The validated model segregated the 
female smokers and non-smokers with AMD with a sensitivity and specificity of 32.5% 
and 82.3% respectively, while for male smokers and non-smokers it was 92.3% and 
50.0%.
 
Figure 3.26: Partial Least Squares Discriminant Analysis (PLS-DA) of urine 
samples of female patients with wet AMD (N= 46) showing separation of samples 
of smokers from non-smokers 
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Figure 3.27: Partial Least Squares Discriminant Analysis (PLS-DA) of urine 
samples of male patients with wet AMD (N= 27) showing separation of samples of 
smokers from non-smokers 
 
The analysis of the NMR spectra of the smokers and non-smokers urine samples 
showed peaks of creatinine and succinate; while smokers in addition showed 7-methyl 
adenine, acetone and purine, non-smokers had ornithine and gallic acid in their urine 
samples (Figure 3.28; Table 3.7). 
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Figure 3.28: NMR spectra of urine samples showing various metabolite peaks in 









Table 3.7: List of metabolites which showed an increase in urinalysis of smokers and 
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This thesis reports on a cross sectional study that investigated the metabolic 
characteristics of serum and urine from patients with dry and wet macular degeneration.  
Until recently this was the largest cohort study in AMD to explore the feasibility of 
separating the two disease entities based on their metabolic profiles and is the first to 
analyse these body fluids. The results show that both serum and urine samples from dry 
and wet AMD can be distinguished by NMR metabolomics. The results may however 
indicate production of different metabolites from the same biological pathways, or an 
increased inflammatory response. The study also showed that samples could be 
separated based on gender and smoking, but these analyses did not suggest any further 
pathways to distinguish them, and therefore would appear to have a minimal role in the 
development of AMD. 
As stated, age-related macular degeneration can present in two forms: wet, characterised 
by choroidal neovascularisation and dry, without choroidal neovascularisation. 
Although there has been extensive research into AMD, the aetiology is still unclear. A 
build-up of drusen is associated with AMD but can also be found in age-matched 
individuals who do not have the disease. Several environment factors have been linked 
to AMD, including smoking, UV light and diet, but the strongest links are genetic.  
Polymorphisms in genes encoding complement factor H, high temperature required 
factor A1 (HTRA1), age-related maculopathy susceptibility protein 2 (ARMS2) and 
proteins involved in lipid metabolism have all been associated with AMD (Shaw et al., 
2016). Activity of Complement Factor H (CFH), an inhibitor of the complement 
pathways, is increased in the retina, linking to the inflammageing response to altered 
self-proteins (Thakkinstain, 2006). The fact that different polymorphisms in CFH gene 
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are associated with susceptibility to AMD in Caucasian and Asian populations, is 
suggestive of the central role of CFH in the pathogenesis of AMD (Horie-Inoue et al., 
2014). HTRA1, is a serine protease that disrupts matrix and can increase VEGF 
production.  
One of the questions commonly raised by clinicians is about the likelihood of a patient 
with dry AMD progressing on to wet AMD. This is significant as time is of essence in 
the management of wet AMD; early identification and prompt intervention with 
pharmacologic treatments can greatly improve visual outcomes in wet AMD. Hence 
researchers have always been interested in identifying the clinical parameters that might 
predict the conversion of dry AMD to wet AMD. The main features such as the 
area/size of drusen, presence of retinal pigment epithelial hypertrophy etc. have already 
been looked into, in an attempt to identify any signs that may predict the risk of 
conversion. The most important risk factor identified so far is the presence of wet AMD 
in the fellow eye: the rate of development of wet AMD in the fellow eye has been 
estimated to be around 40% (Silva R et al., 2011).   
Metabolomics, with its inherent multiplexed analysis, has enabled us to generate 
fingerprints of changes in blood and urine metabolites in patients with AMD. NMR 
spectral analysis showed good clustering as well as separation among the serum and 
urine samples from dry and wet AMD patients (Figures 3.3, 3.4, 3.9 and 3.10). The 
variance was more pronounced when orthogonal signal correction was applied as it 
utilises information related to structured variance, removing residual variance or noise. 
This was more so in urine samples than the serum, the significance of which is not clear 
at this stage. It was interesting to note the presence of some of the dry serum samples 
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clustering along with the wet samples. This could be indicative of the initial common 
pathway for dry and wet AMD, or an overlap in the pathways involved due to the 
ongoing degenerative process, at least during part of their progression (Table 4.1; Fig. 
4.1a and 4.1b). It would be interesting to carry out a longitudinal analysis of these dry 
AMD patients, and to look for any changes in metabolites associated with the 
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Wet AMD serum Dry AMD serum 
Lactate Glycolysis Arginine Urea cycle 
Xanthine Purine/Urea cycle Methyl guanine Inflammation 
Galic acid ? Dietary Gallic acid ? Dietary 
Pyridoxal Amino acid metabolism Uracil Pyrimidine 
Glycine Creatine Ornithine Urea cycle 
Succinate TCA cycle Succinic acid TCA cycle 
Wet AMD Urine Dry AMD Urine 
Ornithine Urea cycle Cholate Bile acid 
Alanine Glycolysis Succinate TCA cycle 
Citrate Glycolysis Acetylsalicylate Aspirin 
Creatinine Creatine  Syringic acid Diet/microbiome 
Hippurate Diet/microbiome Isovaleroglycine Fatty acids 
Trimethyl-N-oxide Diet/microbiome N-phenylacetylglycine Fatty acids 
Table 4.1: Metabolites and the associated metabolic pathways  
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Fig. 4.1b: Vitamin B6 metabolism  
[image from http://mpmp.huji.ac.il/maps/vitaminB6metpath.html] 
 
Despite the clustering, the samples also showed peaks of different metabolites in the dry 
and wet AMD samples. This could perhaps indicate a different aspect of the disease 
process or that similar pathways were involved but levels of metabolites were greater in 
one form or the other. This could also be reflective of the influence of systemic 
inflammation or oxidative stress or alternative complement pathway alteration affecting 
the ageing process.  
The NMR spectra of serum samples showed increase in lactate in patients with wet 
AMD.  Retinal adenosine triphosphate (ATP) is mainly generated by glycolysis 
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(Yokosako et al., 2014). Pyruvate, the end-product of glycolysis, is usually converted to 
acetyl-CoA and CO2 in the mitochondria via the tricarboxylic acid (TCA) cycle in 
aerobic conditions; however, in the anaerobic state, it is converted to lactate. It has been 
suggested that inhibition of glycolysis may promote the development and progression of 
AMD. High lactate/pyruvate ratio is indicative of mitochondrial impairment and poor 
oxidative function in AMD. Yokosako et al (2014) hypothesized that decreased 
pyruvate kinase activity in glycolysis would promote the development and progression 
of AMD. The urinalysis by Yokosako et al (2014) showed high lactate/pyruvate ratio in 
wet AMD patient group compared to those without AMD. In our cohort, serum analysis 
of wet AMD patients, but not dry AMD, showed high levels of lactate; this was 
however not seen in the urine samples. The absence of lactate peaks in the dry AMD 
cohort is intriguing, the implication of which needs further investigation. One 
possibility is the increased oxidative stress leading to wet AMD, with macrophage 
activation and infiltration responsible in part for lactate production.  
α-hydroxy butyrate was found elevated in the serum samples of smokers with wet 
AMD. α-hydroxy butyrate is derived from α-keto butyrate, a product of amino acid 
catabolism. It is thought to be an early marker for both insulin resistance and impaired 
glucose regulation, due to increased lipid oxidation and oxidative stress. This further 
supports the observation by Yokosako et al on the role of glycolysis in the pathogenesis 
of AMD. It may be further indicative of the added contribution of smoking to the 
already existing oxidative stress. 
In our cohort, a high level of succinate was noted in both wet and dry serum samples, 
and in urine samples from dry AMD patients. Succinate is an intermediate in the TCA 
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cycle. An imbalance between energy demand and supply of oxygen has been thought to 
cause accumulation of succinate in the mitochondria and extracellular environment, 
which is indicative of mitochondrial stress (Sadagopan N et al., 2007). In response to 
activation, many cells including macrophages alter their metabolic pathway, to support 
production of cytokines and other products, characterised by TCA cycle intermediates 
such as succinate, citrate and fumarate. As these metabolites are found in both serum 
and urine in dry and wet AMD, this would support a systemic inflammageing 
phenotype that both drives and is exacerbated by AMD. In healthy individuals M2 
macrophages protect the retina, while in AMD proinflammatory M1 macrophages drive 
inflammation and M2 macrophages produce increased VEGF that increase 
neovascularisation. (Wu et al 2010).  
Another molecule observed to be at high concentration in the serum samples from dry 
AMD patients was arginine. This high arginine level may be indicative of high nitric 
oxide (NO) production. NO is an important intercellular signalling molecule; it is 
synthesized from arginine by NO synthase (NOS) in vascular endothelium. One of the 
main roles of NO is as a vasoactive mediator. Nitric Oxide is also a chief component of 
cigarette smoke (CS), a risk factor implicated in the pathogenesis of AMD.  CS and NO 
induce RPE apoptosis, vascular permeability, and angiogenesis unless neutralized. NO 
from CS or neuronal nitric oxide synthase (nNOS), the predominant isoform in the RPE, 
could injure the RPE by impairing the Nrf2 (cytoprotective transcription factor) 
response. Both in vitro and in vivo studies suggest that NO is involved in the control of 
retinal blood flow (Veriac S et al., 1993). Intriguingly, the link between AMD and UV 
light has been well researched but a causative mechanism has not been found. Recent 
studies have shown that, in addition to inducing vitamin D, UV is a potent inducer of 
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NO. UV light has been shown to be protective in cardiovascular disease in a vitamin D 
independent mechanism due to NO production (Weller et al., 2016). It is possible that 
while being cardioprotective via maintaining vascular growth and health, increased NO 
may be deleterious in patients with AMD. Seizure disorders are observed two to three-
fold more in the elderly over the age of 75 years (Ramsay RE et al., 2004). Oxidative 
damage increases with age, one of the suggested mechanism being mitochondrial 
impairment. Excessive NO (as reactive nitrogen species (RNS)) causes impairment of 
mitochondrial functions which can result in seizures and neurotoxicity (Shin EJ et al, 
2011; Gupta et al, 2004).  
 
As stated, oxidative stress has a major role in AMD and other diseases of ageing. 
Glutathione (GSH) is a major water-soluble antioxidant. GSH acts as a reductant of 
peroxides either by a non-enzymatic reaction or by a reaction catalysed by glutathione 
peroxidase (Rathbun et al., 1989). Our serum samples showed decrease in GSH levels 
in dry AMD patients. This reinforces the findings of Samiec et al (1998) whose studies 
showed decrease in GSH levels with ageing along with a concomitant increase in 
oxidised glutathione (GSSH) levels (Samiec PS et al., 1998). They also found a 
significantly lower level of plasma GSH in AMD patients, compared to younger 
patients. A closer look into the GSH levels in our serum samples from wet AMD 
patients would be beneficial in understanding the significance of this finding in dry 
AMD samples. 
 
In the urine sample analysis, there was clear separation of dry and wet AMD, 
particularly on orthogonal analysis. However, the peaks represented different 
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metabolites compared to the serum samples. Alanine was the major metabolite peak 
identified in wet AMD urine. In experimental models, it has been proposed that glucose 
in the retinal glial cells is converted to alanine, which maintains the redox potential, 
contributing to NH3 homeostasis. Similar activity was noted in the purified 
photoreceptor suspensions as well. Further study is needed to assess the role of NH3 
homeostasis in AMD (Tsacopoulos et al., 1994). However, even though the metabolites 
may differ, similar pathways are indicated, such as the TCA cycle, urea cycle and those 
linked to oxidative stress.  
The current data on NMR analysis of serum and urine samples can be compared to 
previous studies of metabolomics in AMD. Osborn et al (2013) analysed the plasma 
samples of 26 patients with wet AMD against 19 control sample with no AMD using 
mass spectrometry. The specific metabolites that distinguished wet AMD patients from 
controls were di- and tripeptides, covalently modified amino acids, bile acids, and 
vitamin D-related metabolites. In their cohort, bile acid was found to be of lower level 
in the AMD group (Osborn M et al., 2013). In our cohort, bile acid (cholate) was noted 
to be elevated in the urine samples of dry AMD patients. Osborn identified metabolites 
such as phenylalanine, tyrosine, glutamine, and aspartate, and described the urea cycle 
as a pathway involved in AMD; this supports our findings of arginine and ornithine in 
urine samples from wet AMD. Osborn et al also identified vitamin D pathway 
metabolites; while these were not identified in the current study, possibly due to the 
different analysis methods, our finding of a potential increase in NO would similarly 
link to UV light exposure.  
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A second study analysed the metabolites in plasma samples from patients with AMD, 
from two different geographic area, Boston, U.S (113 patients and 40 controls) and 
Coimbra, Central Portugal (201 patients 42 controls) by NMR spectroscopy (Laíns I et 
al., 2017). Interestingly the results show distinct metabolic profile of AMD patients 
from the two sampling areas compared to their own controls. The authors suggest that 
the differences are due to the influence of nutrition, life style habits and environment on 
the development of AMD. The patients were classified as having early, intermediate or 
late (wet) AMD. In dry AMD (early and intermediate AMD) patients, acetate, creatine, 
dimethyl sulfone, cholesterol, HDL, choline and unsaturated fatty acids were found to 
be elevated in Coimbra subjects, while glutamine, histidine, unsaturated fatty acids and 
albumin, in Boston subjects. No such difference was described in wet AMD cohort (late 
AMD). In our cohort, high level of creatinine was seen in urine samples of wet AMD 
patients, but not in serum samples or in dry AMD patients. In support of the current 
study, where increase in succinate and creatinine was found in smokers and non-
smokers, Lains et al found that smoking, gender and age had little influence in either 
cohort. Future studies could include whether non-smokers had ever smoked and for how 
long. Moreover, as smoking history is a volunteered information and passive smoking 
among non-smoker cannot be ruled out, we cannot attribute much weightage to this 
finding alone.  
It is unlikely that the metabolites identified in all three studies were only derived from 
the eye. Rather the profiles might define an underlying systemic response such as 
inflammageing or atherosclerosis that in susceptible individuals could lead to the retinal 
damage characteristic of AMD. 
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Limitations of the study 
The study cohort reflected real-life AMD patients attending the medical retina clinic; as 
such, the number of patients belonging to the various sub-types of AMD may still be 
too small to enable us to do sub-analysis on the differences in metabolites in these 
categories of patients. With the other published studies, it should be able to provide 
power calculations for future studies. Secondly, the effects of treatment were not 
analysed in this study as only patients with wet AMD would be on some form of 
treatment. Moreover, the influence of anti-VEGF treatment in the metabolomic status of 
our patients was complicated as various patients were on different stages of their 
treatment, having received different numbers of injection. It would be beneficial to do a 
longitudinal analysis, looking into the changes in metabolites before and during 
treatment. Finally, the influence of genetics was not analysed in this study.  
 
Conclusion  
The results of our study show that metabolomics can separate serum and urine samples 
from patients with dry AMD from those with wet AMD. Certain biological pathways 
were identified, some of which have been previously reported and some which are 
novel. However, the pathways identified may be present in both dry and wet AMD, and 
the concentration of the metabolite or the extent of the damage in the retina may have 
led to the difference. A second and not mutually exclusive possibility is that the genetic 
polymorphisms associated with AMD are influencing the metabolomic data. This may 
also have a role to play in the different profiles identified by Lains et al (2017) in their 
two cohorts. The results from studies by Osborn and Lains together show the potential 
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for metabolomics in the investigation of AMD. The data at the moment does not support 
the potential identification of patients with dry AMD who will progress to wet AMD. 
 
Future work 
Our study as well as published literature have shown that metabolomics has a role in 
differentiating dry and wet macular degeneration. These studies have helped us identify 
some of the metabolic pathways involved in the pathogenesis of this complex 
multifactorial disease entity. However, it has also raised several pertinent questions. Our 
future work is intended to try and answer some of these questions. 
• Would metabolomic profiling be able to predict progression of dry AMD to wet 
AMD? Long term follow-up and longitudinal sampling of dry AMD patients 
could give us further insight into the changes in their metabolomic profile and 
disease progression.  
• Would metabolomic studies help to develop new treatment options? Better 
understanding of the difference in metabolomic profile at various stages of the 
disease process may enable further studies to explore specific interventions at 
the relevant metabolic pathways that might alter the course of the disease. This 
could also help to identify possible influences that might trigger the conversion 
of dry AMD to wet AMD, and to investigate the effect of potential interventions 
that would modify those influences. 
• Would metabolomic studies help to identify population at risk of developing a 
disease? Patients would require to be genetically typed for known 
polymorphisms to determine the influence of genes on metabolic pathways. If 
specific metabolites can be identified from a urine or blood sample that is unique 
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to the genetic polymorphisms known to influence the onset, progression and 
long-term outcome, it could pave way for early identification of population at 
risk for developing the disease.  
• How to improve the efficiency of metabolomic screening tools? Different 
methodologies such as mass spectroscopy and NMR could be carried out on the 
same samples to improve the metabolite detection rate. As more metabolites are 
identified, we will be able to understand more about the various pathways 
involved and their influences in the manifestation of the disease process. 
• How to explain the difference in metabolomic profiles observed in Spanish and 
Boston populations? In response to the data from Lains et al, more detailed 
demographic data beyond gender and smoking would be necessary to separate 
biological from environmental influences on AMD. Deep phenotyping with 
detailed demographic data including ethnicity, body mass index (BMI) and 
dietary habits could shine light on some of the variable findings and overlaps 
seen for the two disease types in different study populations. As the Spanish and 
Boston population in the Lains et al study showed different metabolites, 
analysing gut microbiome would be another interesting line of work. 
 
Metabolomics-genome-wide association studies (mGWAS) have uncovered many 
metabolic quantitative trait loci (mQTLs) influencing human metabolic individuality. 
Linking metabolites to known genetic variants associated with AMD, and the potential 
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